Publications

Journals

• Felter SP; Conolly RB; Bercu JP; Bolger PM; Boobis AR; Bos PMJ; Carthew P; Doerrer NG; et alGoodman JI; Harrouk WA; Kirkland DJ; Lau SS; Llewellyn GC; Preston RJ; Schoeny R; Schnatter AR; Tritscher A; van Velsen F; Williams GM. (1 Jul 2011). A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. CRITICAL REVIEWS IN TOXICOLOGY. 41:507-544. Author weblink DOI.
• Adler S; Basketter D; Creton S; Pelkonen O; van Benthem J; Zuang V; Andersen KE; Angers-Loustau A; et alAptula A; Bal-Price A; Benfenati E; Bernauer U; Bessems J; Bois FY; Boobis A; Brandon E; Bremer S; Broschard T; Casati S; Coecke S; Corvi R; Cronin M; Daston G; Dekant W; Felter S; Grignard E; Gundert-Remy U; Heinonen T; Kimber I; Kleinjans J; Komulainen H; Kreiling R; Kreysa J; Leite SB; Loizou G; Maxwell G; Mazzatorta P; Munn S; Pfuhler S; Phrakonkham P; Piersma A; Poth A; Prieto P; Repetto G; Rogiers V; Schoeters G; Schwarz M; Serafimova R; Tähti H; Testai E; van Delft J; van Loveren H; Vinken M; Worth A; Zaldivar JM. (May 2011). Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol. 85:367-485. DOI.
• Boobis A; Budinsky R; Collie S; Crofton K; Embry M; Felter S; Hertzberg R; Kopp D; et alMihlan G; Mumtaz M; Price P; Solomon K; Teuschler L; Yang R; Zaleski R. (May 2011). Critical analysis of literature on low-dose synergy for use in screening chemical mixtures for risk assessment. Crit Rev Toxicol. 41:369-383.
• Meek ME; Boobis AR; Crofton KM; Heinemeyer G; Raaij MV; Vickers C. (2 Apr 2011). Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regul Toxicol Pharmacol. DOI.
• Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; et alNaisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA. (Apr 2011). Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 10:292-306. DOI.
• Koster S; Boobis AR; Cubberley R; Hollnagel HM; Richling E; Wildemann T; Würtzen G; Galli CL. (Aug 2011). Application of the TTC concept to unknown substances found in analysis of foods. Food Chem Toxicol. 49:1643-1660. DOI.
• Carmichael N; Bausen M; Boobis AR; Cohen SM; Embry M; Fruijtier-Pölloth C; Greim H; Lewis R; et alBette Meek ME; Mellor H; Vickers C; Doe J. (Mar 2011). Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. Crit Rev Toxicol. 41:175-186. DOI.
• Dorne JL; Kass GE; Bordajandi LR; Amzal B; Bertelsen U; Castoldi AF; Heppner C; Eskola M; et alFabiansson S; Ferrari P; Scaravelli E; Dogliotti E; Fuerst P; Boobis AR; Verger P. (2011). Human risk assessment of heavy metals: principles and applications. Met Ions Life Sci. 8:27-60.
• Hoekstra J; Hart A; Boobis A; Claupein E; Cockburn A; Hunt A; Knudsen I; Richardson D; et alSchilter B; Schütte K; Torgerson PR; Verhagen H; Watzl B; Chiodini A. (27 May 2010). BRAFO tiered approach for benefit-risk assessment of foods. Food Chem Toxicol. DOI.
• McGregor D; Boobis A; Binaglia M; Botham P; Hoffstadt L; Hubbard S; Petry T; Riley A; et alSchwartz D; Hennes C. (Mar 2010). Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). Crit Rev Toxicol. 40:245-285. DOI.
• Boobis AR. (1 Mar 2010). Proceedings of the Final Congress of COST Action B25: Physiologically Based Pharmaco-Toxicokinetics and Dynamics, held in Athens, 26-27 May 2009. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 106:145-145. DOI.
• Boobis AR. (Mar 2010). Food and Chemical Toxicology publishes papers that further scientific understanding of issues of public concern. Food Chem Toxicol. 48:771. DOI.
• Boobis AR. (Mar 2010). Mode of action considerations in the quantitative assessment of tumour responses in the liver. Basic Clin Pharmacol Toxicol. 106:173-179. DOI.
• Koh YK; Chiu TY; Paterakis N; Boobis A; Scrimshawe MD; Lester JN; Cartmell E. (1 Dec 2009). Fate and occurrence of alkylphenolic compounds in sewage sludges determined by liquid chromatography tandem mass spectrometry. Environ Technol. 30:1415-1424. DOI.
• Boobis AR; Cohen SM; Doerrer NG; Galloway SM; Haley PJ; Hard GC; Hess FG; Macdonald JS; et alThibault S; Wolf DC; Wright J. (Oct 2009). A data-based assessment of alternative strategies for identification of potential human cancer hazards. Toxicol Pathol. 37:714-732. DOI.
• Koh YK; Chiu TY; Boobis AR; Scrimshaw MD; Bagnall JP; Soares A; Pollard S; Cartmell E; et alLester JN. (1 Sep 2009). Influence of operating parameters on the biodegradation of steroid estrogens and nonylphenolic compounds during biological wastewater treatment processes. Environ Sci Technol. 43:6646-6654.
• Julien E; Boobis AR; Olin SS; Ilsi Research Foundation Threshold Working Group. (Sep 2009). The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr. 49:682-689. DOI.
• Kapitulnik J; Pelkonen O; Gundert-Remy U; Dahl SG; Boobis AR. (Jul 2009). Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. Expert Opin Ther Targets. 13:867-887. DOI.
• Chiu TY; Koh YKK; Paterakis N; Boobis AR; Cartmell E; Richards KH; Lester JN; Scrimshaw MD. (12 Jun 2009). The significance of sample mass in the analysis of steroid estrogens in sewage sludges and the derivation of partition coefficients in wastewaters. JOURNAL OF CHROMATOGRAPHY A. 1216:4923-4926. Author weblink DOI.
• Zhu Z; Edwards RJ; Boobis AR. (1 Jun 2009). Increased Expression of Histone Proteins during Estrogen-Mediated Cell Proliferation. ENVIRONMENTAL HEALTH PERSPECTIVES. 117:928-934. Author weblink DOI.
• Boobis AR; Daston GP; Preston RJ; Olin SS. (1 Jan 2009). Application of Key Events Analysis to Chemical Carcinogens and Noncarcinogens. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION. 49:690-707. Author weblink DOI.
• Boobis A; Watelet JB; Whomsley R; Benedetti MS; Demoly P; Tipton K. (2009). Drug interactions. Drug Metab Rev. 41:486-527. DOI.
• Meek ME; Berry C; Boobis AR; Cohen SM; Hartley M; Munn S; Olin S; Schlatter J; et alVickers C. (Oct 2008). Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of action frameworks: a critical analysis. Journal of Toxicology and Environmental Health, Part B, 11(1): 16-31. J Toxicol Environ Health B Crit Rev. 11:681-683. DOI.
• Zhu Z; Edwards RJ; Boobis AR. (26 Sep 2008). Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). Toxicol Lett. 181:93-103. DOI.
• Koh YKK; Chiu TY; Boobis AR; Cartmell E; Pollard SJT; Scrimshaw MD; Lester JN. (1 Sep 2008). A sensitive and robust method for the determination of alkylphenol polyethoxylates and their carboxylic acids and their transformation in a trickling filter wastewater treatment plant. CHEMOSPHERE. 73:551-556. Author weblink DOI.
• Martin O; Shialis T; Lester J; Scrimshaw M; Boobis A; Voulvoulis N. (Sep 2008). Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Cien Saude Colet. 13:1601-1618.
• Boobis AR; Ossendorp BC; Banasiak U; Hamey PY; Sebestyen I; Moretto A. (15 Aug 2008). Cumulative risk assessment of pesticide residues in food. TOXICOLOGY LETTERS. 180:137-150. Author weblink DOI.
• Martin OV; Shialis T; Boobis AR; Voulvoulis N; Lester JN; Scrimshaw MD. (Aug 2008). Defective spermatogenesis: martin et Al. Respond. Environ Health Perspect. 116:A332-A332. Publisher weblink DOI.
• Zhu Z; Boobis AR; Edwards RJ. (May 2008). Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics. Proteomics. 8:1987-2005. DOI.
• Koh YK; Chiu TY; Boobis A; Cartmell E; Scrimshaw MD; Lester JN. (Mar 2008). Treatment and removal strategies for estrogens from wastewater. Environ Technol. 29:245-267. DOI.
• Martin OV; Shialis T; Lester JN; Scrimshaw MD; Boobis AR; Voulvoulis N. (Feb 2008). Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Environ Health Perspect. 116:149-157. DOI.
• Boobis AR; Doe JE; Heinrich-Hirsch B; Meek ME; Munn S; Ruchirawat M; Schlatter J; Seed J; et alVickers C. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol. 38:87-96. DOI.
• Pelkonen O; Kapitulnik J; Gundert-Remy U; Boobis AR; Stockis A. (1 Jan 2008). Local kinetics and dynamics of xenobiotics. CRITICAL REVIEWS IN TOXICOLOGY. 38:697-720. Author weblink DOI.
• d'Yvoire MB; Prieto P; Blaauboer BJ; Bois FY; Boobis A; Brochot C; Coecke S; Freidig A; et alGundert-Remy U; Hartung T; Jacobs MN; Lave T; Leahy DE; Lennernaes H; Loizou GD; Meek B; Pease C; Rowland M; Spendiff M; Yang J; Zeilmaker M. (1 Dec 2007). Physiologically-based kinetic modelling (PBK modelling): Meeting the 3Rs agenda. ATLA-ALTERNATIVES TO LABORATORY ANIMALS. 35:661-671. Author weblink.
• Bouvier d'Yvoire M; Prieto P; Blaauboer BJ; Bois FY; Boobis A; Brochot C; Coecke S; Freidig A; et alGundert-Remy U; Hartung T; Jacobs MN; Lavé T; Leahy DE; Lennernäs H; Loizou GD; Meek B; Pease C; Rowland M; Spendiff M; Yang J; Zeilmaker M. (Dec 2007). Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern Lab Anim. 35:661-671.
• Koh YK; Chiu TY; Boobis A; Cartmell E; Lester JN; Scrimshaw MD. (30 Nov 2007). Determination of steroid estrogens in wastewater by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr A. 1173:81-87. DOI.
• Fang M; Boobis AR; Edwards RJ. (Nov 2007). Searching for novel biomarkers of centrally and peripehrally-acting neurotoxicants, using surface-enhanced laser desorption/ionisation-time-of-flight mass spectrometry (SELDI-TOF MS). Food Chem Toxicol. 45:2126-2137. DOI.
• McGregor D; Boobis A; Botharn P; Hennes C; Hoffstadt L; Hubbard S; Malinverno G; Petry T; et alSchwartz D; Riley A. (7 Oct 2007). Classification of carcinogens under the GHS: Proposals for guidance. TOXICOLOGY LETTERS. 172:S22-S22. Author weblink DOI.
• Martin OV; Lester JN; Voulvoulis N; Boobis AR. (Aug 2007). Human health and endocrine disruption: a simple multicriteria framework for the qualitative assessment of end point specific risks in a context of scientific uncertainty. Toxicol Sci. 98:332-347. DOI.
• Edwards RJ; Wrigley A; Bai Z; Bateman M; Russell H; Murray S; Lu H; Taylor GW; et alBoobis AR; Sriskandan S. (May 2007). C-terminal antibodies (CTAbs): a simple and broadly applicable approach for the rapid generation of protein-specific antibodies with predefined specificity. Proteomics. 7:1364-1372. DOI.
• Canaparo R; Nordmark A; Finnström N; Lundgren S; Seidegård J; Jeppsson B; Edwards RJ; Boobis AR; et alRane A. (Apr 2007). Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin Pharmacol Toxicol. 100:240-248. DOI.
• Boobis A; Contor L; Kind P; Mueller D; Rechkemmer G; Verhagen H; Szoradi A. (1 Jan 2007). BRAFO - Risk-benefit analysis of foods. ANNALS OF NUTRITION AND METABOLISM. 51:393-394. Author weblink.
• Boobis AR. (2007). Risk assessment of dietary supplements. Novartis Found Symp. 282:3-25.
• Barter ZE; Bayliss MK; Beaune PH; Boobis AR; Carlile DJ; Edwards RJ; Houston JB; Lake BG; et alLipscomb JC; Pelkonen OR; Tucker GT; Rostami-Hodjegan A. (1 Jan 2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. CURRENT DRUG METABOLISM. 8:33-45. Author weblink DOI.
• Cohen SM; Boobis AR; Meek ME; Preston RJ; McGregor DB. (Nov 2006). 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans. Crit Rev Toxicol. 36:803-819. DOI.
• Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W. (Nov 2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol. 36:781-792. DOI.
• Dellarco VL; McGregor D; Berry SC; Cohen SM; Boobis AR. (Nov 2006). Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action. Crit Rev Toxicol. 36:793-801. DOI.
• Boobis AR. (20 Sep 2006). Dose-dependent transitions in mechanisms of toxicity: Concluding remarks. TOXICOLOGY LETTERS. 164:S37-S38. Author weblink DOI.
• Boobis AR; Cohen SM; Dellarco V; McGregor D; Vickers C; Willcocks D; Farland W. (20 Sep 2006). IPCS framework for analysing the relevance of a cancer mode of action for humans. TOXICOLOGY LETTERS. 164:S254-S255. Author weblink DOI.
• Boobis AR. (20 Sep 2006). OMICS research adds substantially to the safety assessment of chemicals: The case against. TOXICOLOGY LETTERS. 164:S28-S28. Author weblink DOI.
• Zhu Z; Boobis AR; Edwards RJ. (20 Sep 2006). Use of protein profiles to characterise concentration-effect curves of mixtures of estrogenic compounds in human breast cell lines. TOXICOLOGY LETTERS. 164:S165-S166. Author weblink DOI.
• Key J; Hodgson S; Omar RZ; Jensen TK; Thompson SG; Boobis AR; Davies DS; Elliott P. (Aug 2006). Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control. 17:759-770. DOI.
• Boobis AR. (1 Jul 2006). P-450 and carcinogenesis. ACTA PHARMACOLOGICA SINICA. 27:24-24. Author weblink.
• Ferrier H; Shaw G; Nieuwenhuijsen M; Boobis A; Elliott P. (Jun 2006). Assessment of uncertainty in a probabilistic model of consumer exposure to pesticide residues in food. Food Addit Contam. 23:601-615. DOI.
• Hakooz N; Ito K; Rawden H; Gill H; Lemmers L; Boobis AR; Edwards RJ; Carlile DJ; et alLake BG; Houston JB. (Mar 2006). Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res. 23:533-539. DOI.
• Bull S; Fletcher K; Boobis AR; Battershill JM. (Mar 2006). Evidence for genotoxicity of pesticides in pesticide applicators: a review. Mutagenesis. 21:93-103. DOI.
• Doe JE; Boobis AR; Blacker A; Dellarco V; Doerrer NG; Franklin C; Goodman JI; Kronenberg JM; et alLewis R; McConnell EE; Mercier T; Moretto A; Nolan C; Padilla S; Phang W; Solecki R; Tilbury L; van Ravenzwaay B; Wolf DC. (1 Jan 2006). A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. CRITICAL REVIEWS IN TOXICOLOGY. 36:37-68. Author weblink DOI.
• Carmichael NG; Barton HA; Boobis AR; Cooper RL; Dellarco VL; Doerrer NG; Fenner-Crisp PA; Doe JE; et alLamb JC; Pastoor TP. (1 Jan 2006). Agricultural chemical safety assessment: A multisector approach to the modernization of human safety requirements. CRITICAL REVIEWS IN TOXICOLOGY. 36:1-7. Author weblink DOI.
• Holsapple MP; Pitot HC; Cohen SM; Boobis AR; Klaunig JE; Pastoor T; Dellarco VL; Dragan YP. (Jan 2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 89:51-56. DOI.
• Boobis AR. (1 Sep 2005). A tiered approach to assessing the toxicology of pesticides. TOXICOLOGY LETTERS. 158:S30-S31. Author weblink.
• Sim SC; Edwards RJ; Boobis AR; Ingelman-Sundberg M. (Sep 2005). CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics. 15:625-631.
• Jones HA; Hamacher K; Clark JC; Schofield JB; Krausz T; Haslett C; Boobis AR. (1 Sep 2005). Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. Toxicol Appl Pharmacol. 207:230-236. DOI.
• Okona-Mensah KB; Battershill J; Boobis A; Fielder R. (Jul 2005). An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution. Food Chem Toxicol. 43:1103-1116. DOI.
• Paul GA; Gibbs JS; Boobis AR; Abbas A; Wilkins MR. (Jul 2005). Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 60:107-112. DOI.
• Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O. (10 Apr 2005). Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003. Toxicol Lett. 156:227-240. DOI.
• O'Leary KA; Edwards RJ; Town MM; Boobis AR. (Jan 2005). Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics. 15:51-60.
• Walters DG; Young PJ; Agus C; Knize MG; Boobis AR; Gooderham NJ; Lake BG. (Sep 2004). Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. Carcinogenesis. 25:1659-1669. DOI.
• Pufulete M; Battershill J; Boobis A; Fielder R. (Aug 2004). Approaches to carcinogenic risk assessment for polycyclic aromatic hydrocarbons: a UK perspective. Regul Toxicol Pharmacol. 40:54-66. DOI.
• Fang M; Edwards RJ; Bartlet-Jones M; Taylor GW; Murray S; Boobis AR. (Jun 2004). Urinary N2-(2'-deoxyguanosin-8-yl)PhIP as a biomarker for PhIP exposure. Carcinogenesis. 25:1053-1062. DOI.
• Kapucuoglu N; Coban T; Raunio H; Pelkonen O; Edwards RJ; Boobis AR; Iscan M. (8 Dec 2003). Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett. 202:17-23.
• Edwards RJ; Boobis AR; Davies DS. (Dec 2003). A strategy for investigating the CYP superfamily using targeted antibodies is a paradigm for functional genomic studies. Drug Metab Dispos. 31:1476-1480. DOI.
• Gilbert EA; Edwards RJ; Boobis AR; Rose S; Jenner P. (Oct 2003). Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. J Neural Transm. 110:1091-1101. DOI.
• Renwick AG; Barlow SM; Hertz-Picciotto I; Boobis AR; Dybing E; Edler L; Eisenbrand G; Greig JB; et alKleiner J; Lambe J; Müller DJ; Smith MR; Tritscher A; Tuijtelaars S; van den Brandt PA; Walker R; Kroes R. (Sep 2003). Risk characterisation of chemicals in food and diet. Food Chem Toxicol. 41:1211-1271.
• Kapucuoglu N; Coban T; Raunio H; Pelkonen O; Edwards RJ; Boobis AR; Iscan M. (10 Jul 2003). Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues. Cancer Lett. 196:153-159.
• Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; et alIngelman-Sundberg M. (Jun 2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 31:755-761.
• Fabrizi L; Taylor GW; Cañas B; Boobis AR; Edwards RJ. (Mar 2003). Adduction of the chloroform metabolite phosgene to lysine residues of human histone H2B. Chem Res Toxicol. 16:266-275. DOI.
• Edwards RJ; Price RJ; Watts PS; Renwick AB; Tredger JM; Boobis AR; Lake BG. (Mar 2003). Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 31:282-288.
• Jones HA; Boobis AR; Hamacher K; Coenen HH; Clark JC. (Mar 2003). PET imaging of pulmonary fibrosis. J Nucl Med. 44:483-484.
• Salonen JS; Nyman L; Boobis AR; Edwards RJ; Watts P; Lake BG; Price RJ; Renwick AB; et alGomez-Lechon MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF; Taavitsainen P; Pelkonen O. (2003). Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. 31:1093-1102.
• Edwards RJ; Price RJ; Watts PS; Renwick AB; Tredger JM; Boobis AR; Lake BG. (2003). Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. 31:282-288.
• Sachse C; Bhambra U; Smith G; Lightfoot TJ; Barrett JH; Scollay J; Garner RC; Boobis AR; et alWolf CR; Gooderham NJ; Colorectal Cancer Study Group. (Jan 2003). Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 55:68-76.
• Boobis A; Gundert-Remy U; Kremers P; Macheras P; Pelkonen O. (Dec 2002). In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci. 17:183-193.
• Yadollahi-Farsani M; Davies DS; Boobis AR. (Nov 2002). The mutational signature of alpha-hydroxytamoxifen at Hprt locus in Chinese hamster cells. Carcinogenesis. 23:1947-1952.
• Zhu Z; Hotchkiss SA; Boobis AR; Edwards RJ. (13 Sep 2002). Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. Biochem Biophys Res Commun. 297:65-70.
• Ferrier H; Nieuwenhuijsen M; Boobis A; Elliott P. (Sep 2002). Current knowledge and recent developments in consumer exposure assessment of pesticides: a UK perspective. Food Addit Contam. 19:837-852. DOI.
• Jones HA; Valind SO; Clark IC; Bolden GE; Krausz T; Schofield JB; Boobis AR; Haslett C. (15 Aug 2002). Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol Appl Pharmacol. 183:46-54.
• Farmer PB; Bartsch H; Boobis A; Chipman K; Gescher A; Kadlubar FF; Manson MM; Phillips DH; et alShuker DEG; Swenberg JA; Tannenbaum SR; Wild CP. (9 May 2002). Basic or applied, it's the interaction that counts - Toxicology must not be driven by politics: it's science that should drive decision-making. NATURE. 417:117-117. Author weblink DOI.
• Aboagye EO; Luthra SK; Brady F; Poole K; Anderson H; Jones T; Boobis A; Burtles SS; et alPrice P. (8 Apr 2002). Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer. 86:1052-1056. DOI.
• Eisenbrand G; Pool-Zobel B; Baker V; Balls M; Blaauboer BJ; Boobis A; Carere A; Kevekordes S; et alLhuguenot JC; Pieters R; Kleiner J. (Feb 2002). Methods of in vitro toxicology. Food Chem Toxicol. 40:193-236.
• Rodriguez-Antona C; Donato MT; Boobis A; Edwards RJ; Watts PS; Castell JV; Gomez-Lechon MJ. (2002). Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. 32:505-520.
• Kappers WA; Edwards RJ; Murray S; Boobis AR. (15 Nov 2001). Diazinon is activated by CYP2C19 in human liver. Toxicol Appl Pharmacol. 177:68-76. DOI.
• Bhambra U; Edwards R; Lightfoot T; Garner C; Boobis A; Gooderham N. (1 Nov 2001). Heterocyclic amines and human colon cancer: Identification of risk factors. TOXICOLOGY. 168:84-86. Author weblink.
• Pelkonen O; Boobis AR; Gundert-Remy U; Action COST B15 Working Group 1. (Nov 2001). In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur J Clin Pharmacol. 57:621-629.
• Murray S; Lake BG; Gray S; Edwards AJ; Springall C; Bowey EA; Williamson G; Boobis AR; et alGooderham NJ. (Sep 2001). Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. Carcinogenesis. 22:1413-1420.
• Pelkonen O; Myllynen P; Taavitsainen P; Boobis AR; Watts P; Lake BG; Price RJ; Renwick AB; et alGómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb PS; Lewis DF. (Jun 2001). Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica. 31:321-343. DOI.
• Andersson TB; Sjöberg H; Hoffmann KJ; Boobis AR; Watts P; Edwards RJ; Lake BG; Price RJ; et alRenwick AB; Gómez-Lechón MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Goldfarb PS; Lewis DF; Corcos L; Guillouzo A; Taavitsainen P; Pelkonen O. (May 2001). An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos. 29:712-720.
• Gooderham NJ; Murray S; Lynch AM; Yadollahi-Farsani M; Zhao K; Boobis AR; Davies DS. (Apr 2001). Food-derived heterocyclic amine mutagens: variable metabolism and significance to humans. Drug Metab Dispos. 29:529-534.
• Boobis AR. (31 Mar 2001). Proceedings of EUROTOX 2000 - The XXXVIII European Congress of Toxicology September 17-20, 2000 London, UK - Preface. TOXICOLOGY LETTERS. 120:IX-IX. Author weblink.
• Schulz TG; Thiel R; Neubert D; Brassil PJ; Schulz-Utermoehl T; Boobis AR; Edwards RJ. (9 Mar 2001). Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. Biochim Biophys Acta. 1546:143-155.
• Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ. (Mar 2001). Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica. 31:135-151. DOI.
• Fabrizi L; Taylor GW; Edwards RJ; Boobis AR. (2001). Adducts of the chloroform metabolite phosgene. Adv Exp Med Biol. 500:129-132.
• Andersson TB; Sjoberg H; Hoffmann KJ; Boobis AR; Watts P; Edwards RJ; Lake BG; Price RJ; et alRenwick AB; Gomez-Lechon MJ; Castell JV; Ingelman-Sundberg M; Hidestrand M; Goldfarb PS; Lewis DF; Corcos L; Guillouzo A; Taavitsainen P; Pelkonen O. (2001). An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. 29:712-720.
• Aarrons L; Balant L; Boobis AR. (2001). COST B15: modelling and drug development. Br J Clin Pharmacol. 52:118-119.
• Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; et alPasanen M. (2001). Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate. 80:193-201.
• Riedl AG; Watts PM; Douek DC; Edwards RJ; Boobis AR; Rose S; Jenner P. (15 Dec 2000). Expression and distribution of CYP2C enzymes in rat basal ganglia. Synapse. 38:392-402. DOI.
• Renwick AB; Watts PS; Edwards RJ; Barton PT; Guyonnet I; Price RJ; Tredger JM; Pelkonen O; et alBoobis AR; Lake BG. (Oct 2000). Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 28:1202-1209.
• Crosbie SJ; Murray S; Boobis AR; Gooderham NJ. (7 Jul 2000). Mass spectrometric detection and measurement of N2-(2'-deoxyguanosin-8-yl)PhIP adducts in DNA. J Chromatogr B Biomed Sci Appl. 744:55-64.
• Piipari R; Savela K; Nurminen T; Hukkanen J; Raunio H; Hakkola J; Mäntylä T; Beaune P; et alEdwards RJ; Boobis AR; Anttila S. (1 Jun 2000). Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer. 86:610-616.
• Schulz-Utermoehl T; Edwards RJ; Boobis AR. (May 2000). Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens. Drug Metab Dispos. 28:544-551.
• Zhu H; Boobis AR; Gooderham NJ. (1 Mar 2000). The food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine activates S-phase checkpoint and apoptosis, and induces gene mutation in human lymphoblastoid TK6 cells. Cancer Res. 60:1283-1289.
• Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J. (1 Sep 1999). Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 58:787-796.
• Raunio H; Hakkola J; Hukkanen J; Lassila A; Päivärinta K; Pelkonen O; Anttila S; Piipari R; et alBoobis A; Edwards RJ. (Jul 1999). Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol. 51:412-417.
• Schulz-Utermoehl T; Bennett AJ; Ellis SW; Tucker GT; Boobis AR; Edwards RJ. (Jun 1999). Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics. 9:357-366.
• Riedl AG; Watts PM; Edwards RJ; Schulz-Utermoehl T; Boobis AR; Jenner P; Marsden CD. (20 Mar 1999). Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Res. 822:175-191.
• Applegren LE; Arnold D; Boisseau J; Boobis AR; Ellis RL; Livingston RC; McLean JG; MacNeil JD; et alMiller MA; Miterna ES; Palermo-Neto; Pinter A; Martinez JLR; Sinhaseni P; Soback S; Wells R; Cernigilia CE; Chamberlain P; Chernausek SD; Fuchs R; Good EAM; Hansen MK; Heitzman RJ; Herrman JL; Mitsumori K; Nord CE; Olsen P; Paakkanen J; Pronk MEJ; Ritter L; Roberts G; Roestal B; Sills RC; Sundlof S; Ungemach FR; Weber N. (1 Jan 1999). Evaluation of certain veterinary drug residues in food - Fiftieth report of the Joint FAO/WHO Expert Committee on Food Additives. EVALUATION OF CERTAIN VETERINARY DRUG RESIDUES IN FOOD. 888:1-95. Author weblink.
• Brooks RA; Gooderham NJ; Edwards RJ; Boobis AR; Winton DJ. (Jan 1999). The mutagenicity of benzo[a]pyrene in mouse small intestine. Carcinogenesis. 20:109-114.
• Lynch AM; Gooderham NJ; Davies DS; Boobis AR. (Nov 1998). Genetic analysis of PHIP intestinal mutations in MutaMouse. Mutagenesis. 13:601-605.
• Watts PM; Riedl AG; Douek DC; Edwards RJ; Boobis AR; Jenner P; Marsden CD. (Sep 1998). Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience. 86:511-519.
• Fielder RJ; Atterwill CK; Anderson D; Boobis AR; Botham P; Chamberlain M; Combes R; Duffy PA; et alLewis RW; Lumley CE; Kimber I; Newall DR. (1 Aug 1998). BTS working party report on in vitro toxicology (vol 16, pg 1, 1997). HUMAN & EXPERIMENTAL TOXICOLOGY. 17:468-468. Author weblink.
• Edwards RJ; Adams DA; Watts PS; Davies DS; Boobis AR. (1 Aug 1998). Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol. 56:377-387.
• Jones HA; Schofield JB; Krausz T; Boobis AR; Haslett C. (Aug 1998). Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am J Respir Crit Care Med. 158:620-628.
• Boobis AR. (1 Jul 1998). Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. RESPIRATORY MEDICINE. 92:2-6. Author weblink DOI.
• Gilbert E; Edwards R; Schulz-Utermoehl T; Boobis A; Rose S; Jenner P. (1 Jul 1998). Expression of P450 enzymes in primary rat ventral mesencephalic culture. BRITISH JOURNAL OF PHARMACOLOGY. 124:U24-U24. Author weblink.
• Boobis AR; McKillop D; Robinson DT; Adams DA; McCormick DJ. (May 1998). Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica. 28:493-506. DOI.
• Riedl AG; Brown CT; Rose S; Schulz-Utermoehl T; Edwards RJ; Boobis AR; Jenner P. (1 Mar 1998). Localisation of CYP2D enzymes in naive rat basal ganglia. BRITISH JOURNAL OF PHARMACOLOGY. 123:U132-U132. Author weblink.
• Edwards RJ; Adams DA; Watts PS; Davies DS; Boobis AR. (1998). Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. 56:377-387.
• Raunio H; Hakkola J; Hukkanen J; Pelkonen O; Edwards R; Boobis A; Anttila S. (1998). Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl. 20:465-469.
• Rich KJ; Boobis AR. (1 Dec 1997). Expression and inducibility of P450 enzymes during liver ontogeny. Microsc Res Tech. 39:424-435. DOI.
• Fielder RJ; Atterwill CK; Anderson D; Boobis AR; Botham P; Chamberlain M; Combes R; Duffy PA; et alLewis RW; Lumley CE; Kimber I; Newall DR. (1 Nov 1997). BTS working party report on in vitro toxicology. HUMAN & EXPERIMENTAL TOXICOLOGY. 16:S1-S40. Author weblink.
• Adams DA; Edwards RJ; Davies DS; Boobis AR. (1 Jul 1997). Specific inhibition of human CYP1A2 using a targeted antibody. Biochem Pharmacol. 54:189-197.
• Clifford CP; Adams DA; Murray S; Taylor GW; Wilkins MR; Boobis AR; Davies DS. (1997). The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol. 52:311-315.
• Gooderham NJ; Murray S; Lynch AM; Yadollahi-Farsani M; Zhao K; Rich K; Boobis AR; Davies DS. (12 May 1997). Assessing human risk to heterocyclic amines. Mutat Res. 376:53-60.
• Jones HA; Sriskandan S; Peters AM; Pride NB; Krausz T; Boobis AR; Haslett C. (Apr 1997). Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J. 10:795-803.
• Watts PM; Riedl AG; Douek DC; Edwards RJ; Boobis AR; Jenner P. (1 Mar 1997). CYP2C13 and tyrosine hydroxylase expression in the 6-hydroxydopamine lesioned (6-OHDA) rat. BRITISH JOURNAL OF PHARMACOLOGY. 120:P123-P123. Author weblink.
• Anttila S; Hukkanen J; Hakkola J; Stjernvall T; Beaune P; Edwards RJ; Boobis AR; Pelkonen O; et alRaunio H. (Mar 1997). Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol. 16:242-249.
• Khatsenko OG; Boobis AR; Gross SS. (7 Feb 1997). Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. Toxicol Lett. 90:207-216.
• Crosbie SJ; Boobis AR; Gooderham NJ. (Feb 1997). Analysis of the N-(deoxyguanosin-8-yl) adduct of the food derived carcinogen PhIP using capillary electrophoresis. Biochem Soc Trans. 25:27S.
• Riedl AG; Watts PM; Edwards RJ; Boobis AR; Jenner P; Marsden CD. (16 Dec 1996). Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Res. 743:324-328.
• Lynch AM; Gooderham NJ; Boobis AR. (Sep 1996). Organ distinctive mutagenicity in MutaMouse after short-term exposure to PhIP. Mutagenesis. 11:505-509.
• Boobis AR; Edwards RJ; Adams DA; Davies DS. (Jul 1996). Dissecting the function of cytochrome P450. Br J Clin Pharmacol. 42:81-89.
• Gooderham NJ; Murray S; Lynch AM; Edwards RJ; Yadollahi-Farsani M; Bratt C; Rich KJ; Zhao K; et alMurray BP; Bhadresa S; Crosbie SJ; Boobis AR; Davies DS. (Jul 1996). Heterocyclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol. 42:91-98.
• Riedl AG; Watts PM; Douek DC; Edwards RJ; Boobis AR; Jenner P. (1 Apr 1996). CYP2E1 is expressed in dopaminergic neurones in the rat substantia nigra. BRITISH JOURNAL OF PHARMACOLOGY. 117:P186-P186. Author weblink.
• Yadollahi-Farsani M; Gooderham NJ; Davies DS; Boobis AR. (Apr 1996). Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine(PhIP) at the Chinese hamsters hprt locus. Carcinogenesis. 17:617-624.
• Rich KJ; Zhao K; Davies DS; Boobis AR; Gooderham NJ. (Mar 1996). Developmental changes in hepatic activation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rabbit. Carcinogenesis. 17:555-558.
• Hakkola J; Pasanen M; Hukkanen J; Pelkonen O; Mäenpää J; Edwards RJ; Boobis AR; Raunio H. (23 Feb 1996). Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol. 51:403-411.
• Riedl AG; Watts PM; Edwards RJ; Boobis AR; Jenner P. (Feb 1996). Brain cytochrome P450 in the rat. Biochem Soc Trans. 24:52S.
• Davies DS; Gooderham NJ; Murray S; Lynch A; de la Torre R; Segura J; Boobis AR. (1996). Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Arch Toxicol Suppl. 18:251-258.
• Boobis AR; Gooderham NJ; Edwards RJ; Murray S; Lynch AM; Yadollahi-Farsani M; Davies DS. (1996). Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Arch Toxicol Suppl. 18:286-302.
• Debri K; Boobis AR; Davies DS; Edwards RJ. (22 Dec 1995). Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol. 50:2047-2056.
• Lynch AM; Murray S; Gooderham NJ; Boobis AR. (Nov 1995). Exposure to and activation of dietary heterocyclic amines in humans. Crit Rev Oncol Hematol. 21:19-31.
• Edwards RJ; Singleton AM; Murray BP; Davies DS; Boobis AR. (6 Jan 1995). Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol. 49:39-47.
• Boobis AR; Gooderham NJ; Rich KJ; Zhao K; Edwards RJ; Murray BP; Lynch AM; Murray S; et alDavies DS. (1995). Enzymatic studies of the activation of heterocyclic food mutagens in man. Princess Takamatsu Symp. 23:134-144.
• Davies DS; Gooderham NJ; Murray S; Lynch A; de la Torre R; Segura J; Boobis AR. (1995). Systemic exposure to dietary heterocyclic amines in man. Princess Takamatsu Symp. 23:190-196.
• Boobis AR. (Dec 1994). Should breast feeding mothers give up meat? Metabolism of the food-derived carcinogen 2-amino-1-methyl-6-phenyl-imidazo [4,5-b] pyridine by lactating Fischer 344 rats and their nursing pups. Hum Exp Toxicol. 13:908-909.
• BOOBIS AR. (1 Aug 1994). 3RD INTERNATIONAL-CONFERENCE ON PRACTICAL IN-VITRO TOXICOLOGY - 25-29 JULY 1993, EAST-MIDLANDS-CONFERENCE-CENTER, NOTTINGHAM, UK - PREFACE. TOXICOLOGY IN VITRO. 8:505-505. Author weblink DOI.
• Boobis AR. (Aug 1994). Preface. Toxicol In Vitro. 8:505.
• BLAAUBOER BJ; BOOBIS AR; CASTELL JV; COECKE S; GROOTHUIS GMM; GUILLOUZO A; HALL TJ; HAWKSWORTH GM; et alLORENZON G; MILTENBURGER HG; ROGIERS V; SKETT P; VILLA P; WIEBEL FJ. (1 Jul 1994). THE PRACTICAL APPLICABILITY OF HEPATOCYTE CULTURES IN ROUTINE TESTING - THE REPORT AND RECOMMENDATIONS OF ECVAM WORKSHOP .1. ATLA-ALTERNATIVES TO LABORATORY ANIMALS. 22:231-241. Author weblink.
• Zhao K; Murray S; Davies DS; Boobis AR; Gooderham NJ. (Jun 1994). Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes. Carcinogenesis. 15:1285-1288.
• Fowler J; Jackson M; Boobis A. (Jun 1994). The 'register of toxicologists'. Hum Exp Toxicol. 13:377-380.
• Edwards RJ; Murray BP; Murray S; Schulz T; Neubert D; Gant TW; Thorgeirsson SS; Boobis AR; et alDavies DS. (May 1994). Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis. 15:829-836.
• Zhao K; Boobis AR; Davies DS; Gooderham NJ. (May 1994). The role of CYP1A enzymes in murine activation of the cooked food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Biochem Soc Trans. 22:128S.
• KHATSENKO OG; BOOBIS AR; GROSS SS; VANE J. (19 Apr 1994). NITRIC-OXIDE REDUCES THE CYTOCHROME-P-450 ACTIVITY AT PRETRANSLATIONAL LEVEL. FASEB JOURNAL. 8:A1249-A1249. Author weblink.
• Brooks RA; Gooderham NJ; Zhao K; Edwards RJ; Howard LA; Boobis AR; Winton DJ. (1 Apr 1994). 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a potent mutagen in the mouse small intestine. Cancer Res. 54:1665-1671.
• Boobis AR; Lynch AM; Murray S; de la Torre R; Solans A; Farré M; Segura J; Gooderham NJ; et alDavies DS. (1 Jan 1994). CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res. 54:89-94.
• LYNCH AM; BOOBIS AR; DAVIES DS; MURRAY S; GOODERHAM N. (15 Dec 1993). INTRAINDIVIDUAL AND INTERINDIVIDUAL VARIABILITY IN SYSTEMIC EXPOSURE IN HUMANS TO 2-AMINO-3,8-DI-METHYLIMIDAZO[4,5-F]QUINOXALINE AND 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE, CARCINOGENS PRESENT IN COOKED BEEF - REPLY. CANCER RESEARCH. 53:6075-6076. Author weblink.
• Edwards RJ; Murray BP; Singleton AM; Murray S; Davies DS; Boobis AR. (20 Jul 1993). Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. Biochem Pharmacol. 46:213-220.
• Rich KJ; Foster JR; Edwards RJ; Davies DS; Boobis AR. (Jun 1993). Ontogenetic development of the distribution of constitutive and 3-methylcholanthrene-induced CYP1A1 and CYP1A2 in rabbit liver. J Histochem Cytochem. 41:915-925.
• MURRAY BP; EDWARDS RJ; DAVIES DS; BOOBIS AR. (15 May 1993). CONSERVATION OF A FUNCTIONALLY IMPORTANT SURFACE REGION BETWEEN 2 FAMILIES OF THE CYTOCHROME-P-450 SUPERFAMILY. BIOCHEMICAL JOURNAL. 292:309-310. Author weblink.
• FIELDER RJ; ALLEN JA; BOOBIS AR; BOTHAM PA; DOE J; ESDAILE DJ; GATEHOUSE DG; HODSONWALKER G; et alMORTON DB; KIRKLAND DJ; RICHOLD M. (1 May 1993). REPORT OF THE BTS UKEMS WORKING GROUP ON DOSE SETTING IN INVIVO MUTAGENICITY ASSAYS. HUMAN & EXPERIMENTAL TOXICOLOGY. 12:189-198. Author weblink.
• Murray BP; Edwards RJ; Murray S; Singleton AM; Davies DS; Boobis AR. (Apr 1993). Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis. 14:585-592.
• Lynch AM; Murray S; Zhao K; Gooderham NJ; Boobis AR; Davies DS. (Feb 1993). Molecular dosimetry of the food-borne carcinogen MeIQx using adducts of serum albumin. Carcinogenesis. 14:191-194.
• Edwards RJ; Murray BP; Murray S; Singleton AM; Davies DS; Boobis AR. (15 Jan 1993). An inhibitory monoclonal anti-protein antibody and an anti-peptide antibody share an epitope on rat cytochrome P-450 enzymes CYP1A1 and CYP1A2. Biochim Biophys Acta. 1161:38-46.
• Boobis AR. (Dec 1992). Molecular basis for differences in susceptibility to toxicants: introduction. Toxicol Lett. 64-65 Spec No:109-113.
• Rich KJ; Murray BP; Lewis I; Rendell NB; Davies DS; Gooderham NJ; Boobis AR. (Dec 1992). N-hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver. Carcinogenesis. 13:2221-2226.
• Davies DS; Fawthrop DJ; Nasseri-Sina P; Wilson JW; Hardwick SJ; Boobis AR. (Dec 1992). Paracetamol toxicity and its prevention by cytoprotection with iloprost. Toxicol Lett. 64-65 Spec No:575-580.
• Lynch AM; Knize MG; Boobis AR; Gooderham NJ; Davies DS; Murray S. (15 Nov 1992). Intra- and interindividual variability in systemic exposure in humans to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 2-amino-1-methyl- 6-phenylimidazo[4,5-b]pyridine, carcinogens present in cooked beef. Cancer Res. 52:6216-6223.
• FIELDER RJ; ALLEN JA; BOOBIS AR; BOTHAM PA; DOE J; ESDAILE DJ; GATEHOUSE DG; HODSONWALKER G; et alMORTON DB; KIRKLAND DJ; RICHOLD M. (1 Sep 1992). DOES SETTING IN INVIVO MUTAGENICITY ASSAYS. MUTAGENESIS. 7:313-319. Author weblink DOI.
• Efthymiopoulos C; Strolin Benedetti M; Sassella D; Boobis A; Davies D. (Sep 1992). Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers. Antimicrob Agents Chemother. 36:1958-1963.
• Fielder RJ; Allen JA; Boobis AR; Botham PA; Doe J; Esdaile DJ; Gatehouse DG; Hodson-Walker G; et alMorton DB; Kirkland DJ. (Sep 1992). Report of British Toxicology Society/UK Environmental Mutagen Society Working Group. Dose setting in in vivo mutagenicity assays. Mutagenesis. 7:313-319.
• Hardwick SJ; Wilson JW; Fawthrop DJ; Boobis AR; Davies DS. (1992). Paracetamol toxicity in hamster isolated hepatocytes: the increase in cytosolic calcium accompanies, rather than precedes, loss of viability. Arch Toxicol. 66:408-412.
• Jones SM; Boobis AR; Moore GE; Stanier PM. (15 Apr 1992). Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem Pharmacol. 43:1876-1879.
• Edwards RJ; Sesardic D; Murray BP; Singleton AM; Davies DS; Boobis AR. (15 Apr 1992). Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily. Biochem Pharmacol. 43:1737-1746.
• Nasseri-Sina P; Fawthrop DJ; Wilson J; Boobis AR; Davies DS. (Feb 1992). Cytoprotection by iloprost against paracetamol-induced toxicity in hamster isolated hepatocytes. Br J Pharmacol. 105:417-423.
• De Matteis F; Dawson SJ; Boobis AR; Comoglio A. (Nov 1991). Inducible bilirubin-degrading system of rat liver microsomes: role of cytochrome P450IA1. Mol Pharmacol. 40:686-691.
• Jones HA; Rhodes CG; Law MP; Becket JM; Clark JC; Boobis AR; Taylor GW. (4 Oct 1991). Rapid analysis for metabolites of 11C-labelled drugs: fate of [11C]-S-4-(tert.-butylamino-2-hydroxypropoxy)-benzimidazol-2-one in the dog. J Chromatogr. 570:361-370.
• EDWARDS RJ; SINGLETON AM; MURRAY BP; MURRAY S; BOOBIS AR; DAVIES DS. (15 Sep 1991). IDENTIFICATION OF A FUNCTIONALLY CONSERVED SURFACE REGION OF RAT CYTOCHROMES-P450IA. BIOCHEMICAL JOURNAL. 278:749-757. Author weblink.
• Gooderham NJ; Soames A; Rice JC; Boobis AR; Davies DS. (Sep 1991). Distribution and elimination of [2-14C]amino-3,8-dimethylimidazo [4, 5-f] quinoxaline in mice. Analysis by whole animal autoradiography. Hum Exp Toxicol. 10:337-345.
• Murray S; Boobis AR. (23 Aug 1991). Combined assay for phenacetin and paracetamol in plasma using capillary column gas chromatography-negative-ion mass spectrometry. J Chromatogr. 568:341-350.
• Lynch AM; Murray S; Boobis AR; Davies DS; Gooderham NJ. (Jun 1991). The measurement of MeIQx adducts with mouse haemoglobin in vitro and in vivo: implications for human dosimetry. Carcinogenesis. 12:1067-1072.
• Edwards RJ; Murray BP; Singleton AM; Boobis AR. (8 Jan 1991). Orientation of cytochromes P450 in the endoplasmic reticulum. Biochemistry. 30:71-76.
• Boobis AR; Gooderham NJ; Murray BP; Murray S; Lynch A; Sesardic D; Davies DS. (1991). Absorption and disposition of MeIQx in man: lessons for human dosimetry. Prog Clin Biol Res. 372:89-98.
• Edwards RJ; Murray BP; Boobis AR. (1991). Antipeptide antibodies in studies of cytochromes P450IA. Methods Enzymol. 206:220-233.
• Fawthrop DJ; Boobis AR; Davies DS. (1991). Mechanisms of cell death. Arch Toxicol. 65:437-444.
• JACKSON PR; BOOBIS AR; TUCKER GT. (1 Jan 1991). PHENOTYPE OR GENOTYPE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 31:119-120. Author weblink.
• Winton DJ; Gooderham NJ; Boobis AR; Davies DS; Ponder BA. (15 Dec 1990). Mutagenesis of mouse intestine in vivo using the Dlb-1 specific locus test: studies with 1,2-dimethylhydrazine, dimethylnitrosamine, and the dietary mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Cancer Res. 50:7992-7996.
• BOOBIS AR; SESARDIC D; MURRAY BP; EDWARDS RJ; SINGLETON AM; RICH KJ; MURRAY S; DELATORRE R; et alSEGURA J; PELKONEN O; PASANEN M; KOBAYASHI S; ZHIGUANG T; DAVIES DS. (1 Nov 1990). SPECIES VARIATION IN THE RESPONSE OF THE CYTOCHROME P-450-DEPENDENT MONOOXYGENASE SYSTEM TO INDUCERS AND INHIBITORS. XENOBIOTICA. 20:1139-1161. Author weblink.
• Boobis AR; Davies DS. (Oct 1990). Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol. 30:653-656.
• Sesardic D; Pasanen M; Pelkonen O; Boobis AR. (Jul 1990). Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis. 11:1183-1188.
• BOOBIS AR; EDWARDS RJ; FOSTER J; RICH KJ. (1 Jul 1990). ONTOGENY OF EXPRESSION, DISTRIBUTION AND INDUCIBILITY OF CYTOCHROMES P450IA1 AND IA2 IN HEPATIC AND EXTRAHEPATIC TISSUES OF THE RAT. EUROPEAN JOURNAL OF PHARMACOLOGY. 183:1502-1502. Author weblink DOI.
• Sesardic D; Boobis AR; Murray BP; Murray S; Segura J; de la Torre R; Davies DS. (Jun 1990). Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 29:651-663.
• BOOBIS AR; SESARDIC D; PASANEN M; PELKONEN O; SEGURA J; DAVIES DS. (1 May 1990). TISSUE SELECTIVE EXPRESSION AND INDUCIBILITY OF MEMBERS OF THE CYTOCHROME P450IA FAMILY IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 29:P603-P604. Author weblink.
• Boobis AR; Seddon CE; Nasseri-Sina P; Davies DS. (15 Apr 1990). Evidence for a direct role of intracellular calcium in paracetamol toxicity. Biochem Pharmacol. 39:1277-1281.
• Boobis AR; Fawthrop DJ; Davies DS. (Apr 1990). Mechanisms of cell toxicity. Curr Opin Cell Biol. 2:231-237.
• Newman CM; Warren JB; Taylor GW; Boobis AR; Davies DS. (Apr 1990). Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-L- but not N-acetyl-D-cysteine. Br J Pharmacol. 99:825-829.
• Edwards RJ; Singleton AM; Murray BP; Sesardic D; Rich KJ; Davies DS; Boobis AR. (1 Mar 1990). An anti-peptide antibody targeted to a specific region of rat cytochrome P-450IA2 inhibits enzyme activity. Biochem J. 266:497-504.
• Cocker J; Boobis AR; Wilson HK; Gompertz D. (Mar 1990). Evidence that a beta-N-glucuronide of 4,4'-methylenebis (2-chloroaniline) (MbOCA) is a major urinary metabolite in man: implications for biological monitoring. Br J Ind Med. 47:154-161.
• Sesardic D; Edwards RJ; Davies DS; Thomas PE; Levin W; Boobis AR. (1 Feb 1990). High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochem Pharmacol. 39:489-498.
• Sesardic D; Cole KJ; Edwards RJ; Davies DS; Thomas PE; Levin W; Boobis AR. (1 Feb 1990). The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. Biochem Pharmacol. 39:499-506.
• Valero F; de la Torre R; Boobis AR; Murray S; Segura J. (1990). Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. J Pharm Biomed Anal. 8:783-787.
• Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR. (Jan 1990). Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol. 29:101-109.
• Gooderham NJ; Murray BP; Murray S; Boobis AR; Davies DS. (1990). Exposure to, and activation of, the food derived mutagenic heterocyclic amine MeIQx. Prog Clin Biol Res. 340B:67-76.
• Edwards RJ; Murray BP; Singleton AM; Davies DS; Boobis AR. (Dec 1989). Identification of surface regions of cytochromes P-450 using anti-peptide antibodies. Biochem Soc Trans. 17:1022-1023.
• Rich KJ; Edwards RJ; Foster JR; Davies DS; Boobis AR. (Dec 1989). Ontogeny of expression, inducibility and distribution of cytochromes P-450 forms 4 and 6 in rabbit liver. Biochem Soc Trans. 17:1023-1024.
• Murray BP; Sesardic D; Davies DS; Boobis AR. (Dec 1989). Species differences in specificity of hydrocarbon-inducible forms of cytochrome P-450. Biochem Soc Trans. 17:1021-1022.
• Rich KJ; Sesardic D; Foster JR; Davies DS; Boobis AR. (1 Oct 1989). Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. Biochem Pharmacol. 38:3305-3322.
• Tu ZG; Seddon CE; Boobis AR; Davies DS. (Sep 1989). Effects of nortriptyline on the activities of human and rat liver microsome bufuralol 1'-hydroxylase in vitro. Zhongguo Yao Li Xue Bao. 10:465-469.
• Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR. (1 Sep 1989). The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol. 38:2795-2799.
• GOODERHAM NJ; RICE JC; NASSERISINA P; BOOBIS AR; DAVIES DS. (1 Aug 1989). ACTIVATION OF THE FOOD CARCINOGEN 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-F]QUINOXALINE BY HEPATOCYTES. BIOCHEMICAL SOCIETY TRANSACTIONS. 17:734-735. Author weblink.
• Boobis AR; Fawthrop DJ; Davies DS. (Jul 1989). Mechanisms of cell death. Trends Pharmacol Sci. 10:275-280.
• Sesardic D; Rich KJ; Edwards RJ; Davies DS; Boobis AR. (Jul 1989). Selective destruction of cytochrome P-450d and associated monooxygenase activity by carbon tetrachloride in the rat. Xenobiotica. 19:795-811.
• MURRAY BP; GOODERHAM NJ; BOOBIS AR; DAVIES DS. (1 Jun 1989). 3,8-DIMETHYL-2-NITRO-IMIDAZO[4,5-F]QUINOXALINE(NITRO-MEIQX) IS A POTENT DIRECT-ACTING MUTAGEN. BIOCHEMICAL SOCIETY TRANSACTIONS. 17:540-541. Author weblink.
• EDWARDS RJ; SINGLETON AM; RICH K; SESARDIC D; MURRAY BP; BOOBIS AR; DAVIES DS. (1 Jun 1989). ANTIBODIES AGAINST RAT CYTOCHROME-P-450D - COMPARISON OF THE PURIFIED PROTEIN AND A SYNTHETIC PEPTIDE AS IMMUNOGENS. BIOCHEMICAL SOCIETY TRANSACTIONS. 17:535-536. Author weblink.
• Edwards RJ; Murray BP; Boobis AR; Davies DS. (2 May 1989). Identification and location of alpha-helices in mammalian cytochromes P450. Biochemistry. 28:3762-3770.
• BOOBIS AR; SPEIRS CJ; MURRAY S; MABADEJE AFB; DAVIES DS. (1 May 1989). DEBRISOQUINE METABOLIC PHENOTYPE IN PATIENTS WITH BRONCHOGENIC-CARCINOMA. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 27:P646-P647. Author weblink.
• BOOBIS AR; MURRAY S; GOODERHAM NJ; DAVIES DS. (1 May 1989). SYSTEMIC EXPOSURE TO A CARCINOGENIC HETEROCYCLIC AMINE FOLLOWING CONSUMPTION OF MEAT. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 27:P709-P709. Author weblink.
• Murray S; Gooderham NJ; Boobis AR; Davies DS. (Apr 1989). Detection and measurement of MeIQx in human urine after ingestion of a cooked meat meal. Carcinogenesis. 10:763-765.
• Edwards RJ; Singleton AM; Boobis AR; Davies DS. (24 Feb 1989). Cross-reaction of antibodies to coupling groups used in the production of anti-peptide antibodies. J Immunol Methods. 117:215-220.
• Gooderham NJ; Murray S; Rice JC; Boobis AR; Davies DS. (1989). Dietary heterocyclic amines and human cancer. Drug Metab Rev. 20:285-305. DOI.
• Balant LP; Gundert-Remy U; Boobis AR; von Bahr C. (1989). Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol. 36:551-554.
• Sesardic D; Boobis AR; Edwards RJ; Davies DS. (Oct 1988). A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 26:363-372.
• Murray S; Gooderham NJ; Boobis AR; Davies DS. (Oct 1988). An assay for 2-amino-3,8-dimethylimidazo[4,5-f]-quinoxaline and 2-amino-3,4,8-trimethylimidazo-[4,5-f]quinoxaline in fried beef using capillary column gas chromatography electron capture negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 16:221-224.
• Edwards RJ; Singleton AM; Sesardic D; Boobis AR; Davies DS. (1 Oct 1988). Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. Biochem Pharmacol. 37:3735-3741.
• Cocker J; Boobis AR; Davies DS. (Sep 1988). Determination of the N-acetyl metabolites of 4,4'-methylene dianiline and 4,4'-methylene-bis(2-chloroaniline) in urine. Biomed Environ Mass Spectrom. 17:161-167.
• NASSERISINA P; SEDDON CE; BOOBIS AR; DAVIES DS. (1 Aug 1988). CYTOPROTECTIVE EFFECTS OF 16,16-DIMETHYL PROSTAGLANDIN-E2 ON PARACETAMOL TOXICITY IN ISOLATED HEPATOCYTES. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:641-642. Author weblink.
• FREEMAN A; BOOBIS AR; GOODERHAM NJ. (1 Aug 1988). HEPATOTOXICITY OF CARBON-TETRACHLORIDE - PROTECTION BY PRETREATMENT OF MICE WITH POLYRIBOINOSINIC ACID POLYRIBOCYTIDYLIC ACID. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:632-633. Author weblink.
• RICH KJ; BOOBIS AR; FOSTER J; SESARDIC D; DAVIES DS. (1 Aug 1988). IMMUNOHISTOCHEMICAL LOCALIZATION OF CYTOCHROME-P-450 B/E IN HEPATIC AND EXTRAHEPATIC RAT-TISSUES. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:642-643. Author weblink.
• MURRAY BP; BOOBIS AR; DELATORRE R; SEGURA J; DAVIES DS. (1 Aug 1988). INHIBITION OF DIETARY MUTAGEN ACTIVATION BY METHYLXANTHINES. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:620-621. Author weblink.
• HASHEMINEJAD G; BOOBIS AR; DAVIES DS. (1 Jul 1988). A COMPARISON OF THE ABILITY OF VARIOUS COMPOUNDS TO INDUCE CYTOCHROME-P-450. HUMAN TOXICOLOGY. 7:383-384. Author weblink.
• GOODERHAM NJ; SOAMES A; RICE JC; BOOBIS AR; DAVIES DS. (1 Jul 1988). DISTRIBUTION AND ELIMINATION OF [C-14]2-AMINO-3,8-DIMETHYLIMIDAZO-(4,5-F)QUINOXALINE. HUMAN TOXICOLOGY. 7:381-382. Author weblink.
• MURRAY BP; BOOBIS AR; SESARDIC D; EDWARDS RJ; DAVIES DS. (1 Jul 1988). THE ROLE OF CYTOCHROME-P-450 LM4 IN THE ACTIVATION OF THE DIETARY CARCINOGEN MEIQX. HUMAN TOXICOLOGY. 7:383-383. Author weblink.
• TU ZG; MURRAY B; SESARDIC D; KOBAYASHI S; MURRAY S; DAVIES DS; BOOBIS AR. (1 May 1988). QUINIDINE DISCRIMINATES BETWEEN RAT AND HUMAN DEBRISOQUINE 4-HYDROXYLASE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 25:P674-P674. Author weblink.
• KOBAYASHI S; SPEIRS CJ; WATSON D; MURRAY S; SESARDIC D; BOOBIS AR. (1 May 1988). TIME COURSE OF INHIBITION BY QUINIDINE OF DEBRISOQUINE 4-HYDROXYLASE ACTIVITY IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 25:P673-P674. Author weblink.
• Murray S; Gooderham NJ; Boobis AR; Davies DS. (Feb 1988). Measurement of MeIQx and DiMeIQx in fried beef by capillary column gas chromatography electron capture negative ion chemical ionisation mass spectrometry. Carcinogenesis. 9:321-325.
• GOODERHAM NJ; RICE JC; BOOBIS AR; DAVIES DS. (1 Jan 1988). DIFFERENCES BETWEEN HEPATIC AND EXTRAHEPATIC TISSUES IN THE ACTIVATION OF MIEQX TO A MUTAGEN IN THE AMES SALMONELLA TEST. HUMAN TOXICOLOGY. 7:79-79. Author weblink.
• DAVIES DS; GOODERHAM NJ; RICE JC; MURRAY S; BOOBIS AR. (1 Jan 1988). MUTAGENIC AMINES IN COOKED FOOD. HUMAN TOXICOLOGY. 7:41-42. Author weblink.
• McManus ME; Davies DS; Boobis AR; Grantham PH; Wirth PJ. (Dec 1987). Guanethidine N-oxidation in human liver microsomes. J Pharm Pharmacol. 39:1052-1055.
• NASSERISINA P; BOOBIS AR; DAVIES DS. (1 Sep 1987). CYTOPROTECTION AGAINST PARACETAMOL-INDUCED TOXICITY IN ISOLATED HEPATOCYTES, WITH ILOPROST, A STABLE ANALOG OF PROSTACYCLIN. HUMAN TOXICOLOGY. 6:429-430. Author weblink.
• GOODERHAM NJ; MURRAY S; BARNES VF; BOOBIS AR; DAVIES DS. (1 Sep 1987). TRP-P-2 - A POTENT MUTAGEN PRESENT IN COOKED MEAT AND FISH. HUMAN TOXICOLOGY. 6:431-431. Author weblink.
• Murray S; Gooderham NJ; Barnes VF; Boobis AR; Davies DS. (Jul 1987). Trp-P-2 is not detectable in cooked meat and fish. Carcinogenesis. 8:937-940.
• EDWARDS RJ; SESARDIC D; BOOBIS AR; DAVIES DS. (1 Jun 1987). LOCATION OF BINDING-SITES FOR MONOCLONAL-ANTIBODIES ON CYTOCHROME-P-450C. BIOCHEMICAL SOCIETY TRANSACTIONS. 15:455-455. Author weblink.
• BOOBIS AR; MURRAY S; SPEIRS CJ; DAVIES DS. (1 May 1987). DOSE DEPENDENT METABOLISM OF PHENACETIN FOLLOWING ORAL-ADMINISTRATION. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 23:P643-P644. Author weblink.
• Tee LB; Davies DS; Seddon CE; Boobis AR. (1 Apr 1987). Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. Biochem Pharmacol. 36:1041-1052.
• Kahn GC; Rubenfield M; Davies DS; Boobis AR. (Feb 1987). Phenacetin O-deethylase activity of the rat: strain differences and the effects of enzyme-inducing compounds. Xenobiotica. 17:179-187. DOI.
• Plummer S; Boobis AR; Davies DS. (Feb 1987). Strain differences in the metabolic activation of aflatoxin B1 in the rat. Xenobiotica. 17:199-208. DOI.
• Boobis AR; Murray S; Seddon CE; Davies DS. (1987). In vitro studies of induction and inhibition of drug oxidation in man. Pharmacol Ther. 33:101-108.
• Foster JR; Elcombe CR; Boobis AR; Davies DS; Sesardic D; McQuade J; Robson RT; Hayward C; et alLock EA. (15 Dec 1986). Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. Biochem Pharmacol. 35:4543-4554.
• Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS. (Dec 1986). Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 22:739-743.
• Boobis AR; Seddon CE; Davies DS. (1 Sep 1986). Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. Biochem Pharmacol. 35:2961-2965.
• HARRIES GC; BOOBIS AR; SESARDIC D; EDWARDS RJ; DAVIES DS. (1 Jun 1986). COMPARATIVE ACTIVATION OF AROMATIC-AMINES TO MUTAGENIC METABOLITES BY HUMAN AND RAT-LIVER. FOOD AND CHEMICAL TOXICOLOGY. 24:757-757. Author weblink DOI.
• Boobis AR; Tee LB; Hampden CE; Davies DS. (Jun 1986). Freshly isolated hepatocytes as a model for studying the toxicity of paracetamol. Food Chem Toxicol. 24:731-736.
• Sesardic D; Boobis AR; McQuade J; Baker S; Lock EA; Elcombe CR; Robson RT; Hayward C; et alDavies DS. (1 Jun 1986). Inter-relatedness of some isoenzymes of cytochrome P-450 from rat, rabbit and human, determined with monoclonal antibodies. Biochem J. 236:569-577.
• COCKER J; BOOBIS AR; DAVIES DS. (1 Jun 1986). ROUTES OF ACTIVATION OF 4,4'-METHYLENEBIS-(2-CHLOROANILINE) AND 4,4'-METHYLENEDIANILINE TO BACTERIAL MUTAGENS. FOOD AND CHEMICAL TOXICOLOGY. 24:755-756. Author weblink DOI.
• TEE LBG; BOOBIS AR; DAVIES DS. (1 May 1986). MECHANISM OF ACTION OF ANTIDOTES USED IN THE TREATMENT OF PARACETAMOL OVERDOSE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 21:P570-P571. Author weblink.
• BOOBIS AR; SPEIRS CJ; MURRAY S; DAVIES DS. (1 Jan 1986). QUINIDINE INHIBITS DEBRISOQUINE 4-HYDROXYLATION. ACTA PHARMACOLOGICA ET TOXICOLOGICA. 59:112-112. Author weblink.
• Tee LB; Boobis AR; Huggett AC; Davies DS. (Apr 1986). Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol. Toxicol Appl Pharmacol. 83:294-314.
• Boobis AR; Whyte C; Davies DS. (Mar 1986). Selective induction and inhibition of the components of 7-ethoxycoumarin O-deethylase activity in the rat. Xenobiotica. 16:233-238.
• Tee LG; Boobis AR; Davies DS. (8 Feb 1986). N-acetylcysteine for paracetamol overdose. Lancet. 1:331-332.
• Murray S; Boobis AR. (Feb 1986). An assay for paracetamol, produced by the O-deethylation of phenacetin in vitro, using gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 13:91-93.
• Plummer S; Boobis AR; Davies DS. (Feb 1986). Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?. Arch Toxicol. 58:165-170.
• Davies DS; Tee LB; Hampden C; Boobis AR. (1986). Acetaminophen toxicity in isolated hepatocytes. Adv Exp Med Biol. 197:993-1003.
• McManus ME; Birkett DJ; Burgess WM; Stupans I; Koenig JA; Boobis AR; Davies DS; Wirth PJ; et alGrantham PH; Thorgeirsson SS. (1986). Flavin-containing monooxygenase activity in human liver microsomes. Adv Exp Med Biol. 197:773-779.
• Vital Durand D; Hampden C; Boobis AR; Park BK; Davies DS. (Jan 1986). Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmacol. 21:1-7.
• Harries GC; Boobis AR; Collier N; Davies DS. (Jan 1986). Interindividual differences in the activation of two hepatic carcinogens to mutagens by human liver. Hum Toxicol. 5:21-26.
• Minchin RF; McManus ME; Boobis AR; Davies DS; Thorgeirsson SS. (Dec 1985). Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. Carcinogenesis. 6:1721-1724.
• Kahn GC; Boobis AR; Brodie MJ; Toverud EL; Murray S; Davies DS. (Jul 1985). Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?. Br J Clin Pharmacol. 20:67-76.
• Kahn GC; Rubenfield M; Davies DS; Murray S; Boobis AR. (Jul 1985). Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos. 13:510-516.
• Gulaid AA; Houghton GW; Boobis AR. (18 Jan 1985). Separation of acebutolol and diacetolol diastereomers by reversed-phase high-performance liquid chromatography. J Chromatogr. 318:393-397.
• Boobis AR; McQuade J; Sesardic D; Robson RT; Hayward C; Lock EA; Elcombe CR; Rose MS; et alDavies DS. (15 May 1985). A monoclonal antibody raised to rat liver cytochrome P-448 (form C) which recognises an epitope common to many other forms of cytochrome P-450. Biochem Pharmacol. 34:1671-1681.
• McPherson GA; Benjamin IS; Boobis AR; Blumgart LH. (Jan 1985). Antipyrine elimination in patients with obstructive jaundice: a predictor of outcome. Am J Surg. 149:140-143.
• Boobis AR; Hampden CE; Murray S; Beaune P; Davies DS. (Jun 1985). Attempts to phenotype human liver samples in vitro for debrisoquine 4-hydroxylase activity. Br J Clin Pharmacol. 19:721-729.
• BOOBIS AR; TEE LBG; HAMPDEN CE; HUGGETT AC; DAVIES DS. (1 Jan 1985). COMPARATIVE ABILITY OF MAN TO ACTIVATE PARACETAMOL TO ITS HEPATOTOXIC METABOLITE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 19:P590-P590. Author weblink.
• Tee LB; Seddon T; Boobis AR; Davies DS. (Mar 1985). Drug metabolising activity of freshly isolated human hepatocytes. Br J Clin Pharmacol. 19:279-294.
• SEDDON T; BOOBIS AR; DAVIES DS. (1 Jan 1985). DRUG-METABOLIZING ACTIVITY OF CRYOPRESERVED RAT AND HUMAN HEPATOCYTES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 20:P546-P547. Author weblink.
• Boobis AR; Murray S; Hampden CE; Davies DS. (1 Jan 1985). Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol. 34:65-71.
• Cocker J; Boobis AR; Gibson JF; Davies DS. (1985). The metabolic activation of 4,4'-methylene-bis-(2-chlorobenzeneamine) to a bacterial mutagen by hepatic postmitochondrial supernatant from human and other species. Environ Mutagen. 7:501-509.
• Boobis AR; Davies DS. (Feb 1984). Multiple forms of human cytochrome P-450. Biochem Soc Trans. 12:78-80.
• White IN; Boobis AR; Davies DS. (1 Feb 1984). Species differences in the hepatic formation of green pigments following the administration of norethindrone. Biochem Pharmacol. 33:459-464.
• Boobis AR; Davies DS. (Jan 1984). Human cytochromes P-450. Xenobiotica. 14:151-185. DOI.
• FOSTER J; ELCOMBE CR; ROBSON RT; HAYWARD C; BOOBIS AR; SESARDIC D; MCQUADE J; DAVIES DS; et alLOCK EA. (1 Jan 1984). IMMUNOHISTOCHEMICAL LOCALIZATION OF CYTOCHROME-P-450 IN CONTROL AND DRUG-INDUCED RAT-TISSUES. JOURNAL OF PATHOLOGY. 143:A326-A326. Author weblink.
• BOOBIS AR; DAVIES DS; SEDDON T; TEE LBG. (1 Jan 1984). ISOLATION AND CHARACTERIZATION OF ADULT HUMAN HEPATOCYTES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 17:P624-P625. Author weblink.
• McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS. (Dec 1984). Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes. Cancer Res. 44:5692-5697.
• Davies DS; Boobis AR. (Aug 1983). Variants of human microsomal enzymes. Biochem Soc Trans. 11:459-460.
• BIRNIE GG; GOUDIE BM; DOCHERTY VR; FORREST G; BOOBIS AR; MCPHERSON GAD; MACSWEEN RN; ALLAN JG; et alWATKINSON G; BRODIE MJ. (1 Jan 1983). A PHARMACOKINETIC APPROACH TO THE ASSESSMENT OF HEPATIC-FUNCTION. SCOTTISH MEDICAL JOURNAL. 28:91-91. Author weblink.
• MURRAY S; KAHN GC; BOOBIS AR; DAVIES DS. (1 Jan 1983). MOLECULAR ASPECTS OF DEBRISOQUINE METABOLISM STUDIED BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY WITH ELECTRON-CAPTURE NEGATIVE-ION CHEMICAL IONIZATION. INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES. 48:89-92. Author weblink DOI.
• BOOBIS AR; HAMPDEN C; MURRAY S; DAVIES DS. (1 Jan 1983). RECIPROCAL INHIBITION OF DEBRISOQUINE AND BUFURALOL OXIDATION IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 16:P218-P219. Author weblink.
• Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS. (Mar 1983). Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol. 23:474-481.
• Boobis AR; Lewis P. (Dec 1982). Drugs in pregnancy. Altered pharmacokinetics. Br J Hosp Med. 28:566-573.
• Brodie MJ; Boobis AR; Hillyard CJ; Abeyasekera G; Stevenson JC; MacIntyre I; Park BK. (Oct 1982). Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther. 32:525-530.
• McPherson GA; Benjamin IS; Boobis AR; Brodie MJ; Hampden C; Blumgart LH. (Sep 1982). Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice. Gut. 23:734-738.
• Pacifici GM; Davies DS; Whyte C; Boobis AR. (Sep 1982). Tissue differences in the ontogeny of inducibility of drug-metabolizing enzymes by 3-methylcholanthrene in the rabbit. Xenobiotica. 12:591-598.
• Kahn GC; Boobis AR; Murray S; Davies DS. (Aug 1982). Differential effects of 3-methylcholanthrene and phenobarbitone treatment on the oxidative metabolism of antipyrine in vitro by microsomal fractions of rat liver. Xenobiotica. 12:509-516.
• Lewis KM; Boobis AR; Slade MB; Davies DS. (1 May 1982). Immunopurification of cytochrome P-448 from microsomal fractions of rabbit liver with retention of metabolic activity. Biochem Pharmacol. 31:1815-1817.
• BRODIE MJ; BOOBIS AR; HAMPDEN C; MCPHERSON GAD; BENJAMIN IS; BLUMGART LH. (1 Jan 1982). ANTIPYRINE AND PARACETAMOL METABOLISM IN OBSTRUCTIVE-JAUNDICE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 13:P277-P278. Author weblink.
• Kahn GC; Boobis AR; Murray S; Brodie MJ; Davies DS. (May 1982). Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol. 13:637-645.
• BOOBIS AR; LEWIS P. (1 Jan 1982). DRUGS IN PREGNANCY - ALTERED PHARMACOKINETICS. BRITISH JOURNAL OF HOSPITAL MEDICINE. 28:566-&. Author weblink.
• BRODIE MJ; BOOBIS AR; HILLYARD CJ; ABEYASEKERA G; STEVENSON JC; MACINTYRE I; PARK BK. (1 Jan 1982). EFFECT OF COMBINATION THERAPY WITH RIFAMPICIN AND ISONIAZID ON VITAMIN-D METABOLISM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 14:P144-P145. Author weblink.
• KAHN GC; BOOBIS AR; MURRAY S; PLUMMER S; BRODIE MJ; DAVIES DS. (1 Jan 1982). ENZYMATIC BASIS FOR THE DEFECTIVE 4-HYDROXYLATION OF DEBRISOQUINE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 13:P594-P594. Author weblink.
• BOOBIS AR; KAHN GC; MURRAY S; BRODIE MJ; DAVIES DS. (1 Jan 1982). EVIDENCE FOR A COMMON DEFECT IN THE IMPAIRED OXIDATION OF SUBSTRATES IN THE DEBRISOQUINE OXIDATION POLYMORPHISM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 14:P602-P603. Author weblink.
• BOOBIS AR; BRODIE MJ; MCMANUS ME; STAIANO N; THORGEIRSSON SS; DAVIES DS. (1 Jan 1982). METABOLISM AND MUTAGENIC ACTIVATION OF 2-ACETYLAMINOFLUORENE BY HUMAN-LIVER AND LUNG. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 136:1193-1201. Author weblink.
• Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS. (Dec 1981). Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol. 12:771-777.
• Brodie MJ; Boobis AR; Hillyard CJ; Abeyasekera G; MacIntyre I; Park BK. (Sep 1981). Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther. 30:363-367.
• Kahn GC; Boobis AR; Blair IA; Brodie MJ; Davies DS. (15 May 1981). A radiometric high-pressure liquid chromatography assay for the simultaneous determination of the three main oxidative metabolites of antipyrine in studies in vitro. Anal Biochem. 113:292-300.
• BOOBIS AR; KAHN GC; WHYTE C; BRODIE MJ; DAVIES DS. (1 Jan 1981). BIPHASIC O-DEETHYLATION OF PHENACETIN AND 7-ETHOXYCOUMARIN BY HUMAN AND RAT-LIVER MICROSOMAL FRACTIONS. BIOCHEMICAL PHARMACOLOGY. 30:2451-2456. Author weblink DOI.
• BOOBIS AR; BRODIE MJ; KAHN GC; TOVERUD EL; BLAIR IA; MURRAY S; DAVIES DS. (1 Jan 1981). COMPARISON OF INVIVO AND INVITRO RATES OF ANTIPYRINE OXIDATION IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 11:P419-P420. Author weblink.
• Toverud EL; Boobis AR; Brodie MJ; Murray S; Bennett PN; Whitmarsh V; Davies DS. (1981). Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 21:155-160.
• Brodie MJ; Boobis AR; Gill M; Mashiter K. (Sep 1981). Does rifampicin increase serum levels of testosterone and oestradiol by inducing sex hormone binding globulin capacity?. Br J Clin Pharmacol. 12:431-433.
• Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR. (Jan 1981). Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 11:89-91.
• Brodie MJ; Boobis AR; Bulpitt CJ; Davies DS. (1981). Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol. 20:39-46.
• BRODIE MJ; BOOBIS AR; HILLYARD CJ; ABEYASEKERA G; MACINTYRE I; PARK BK. (1 Jan 1981). INHIBITION BY ISONIAZID OF VITAMIN-D METABOLISM IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 11:P422-P422. Author weblink.
• Boobis AR; Brodie MJ; McManus ME; Staiano N; Thorgeirsson SS; Davies DS. (1981). Metabolism and mutagenic activation of 2-acetylaminofluorene by human liver and lung. Adv Exp Med Biol. 136 Pt B:1193-1201.
• Boobis AR; Slade MB; Stern C; Lewis KM; Davies DS. (5 Oct 1981). Monoclonal antibodies to rabbit liver cytochrome P-448. Life Sci. 29:1443-1448.
• Benford DJ; Bridges JW; Boobis AR; Kahn GC; Brodie MJ; Davies DS. (15 Jun 1981). The selective activation of cytochrome P-450 dependent microsomal hydroxylases in human and rat liver microsomes. Biochem Pharmacol. 30:1702-1703.
• Pacifici GM; Boobis AR; Brodie MJ; McManus ME; Davies DS. (Feb 1981). Tissue and species differences in enzymes of epoxide metabolism. Xenobiotica. 11:73-79. DOI.
• Murray S; Boobis AR; Frank H; Baillie TA; Davies DS. (Oct 1980). Stereoselective excretion of (3-methoxy-4-sulphooxyphenyl)ethylene glycol (MHPG sulphate) in the dog. Naunyn Schmiedebergs Arch Pharmacol. 314:89-96.
• Brodie MJ; Boobis AR; Dollery CT; Hillyard CJ; Brown DJ; MacIntyre I; Park BK. (Jun 1980). Rifampicin and vitamin D metabolism. Clin Pharmacol Ther. 27:810-814.
• Brodie MJ; Boobis AR; Toverud EL; Ellis W; Murray S; Dollery CT; Webster S; Harrison R. (May 1980). Drug metabolism in white vegetarians. Br J Clin Pharmacol. 9:523-525.
• Kahn GC; Boobis AR; Blair I; Brodie MJ; Davies DS. (Mar 1980). Antipyrine as an in vitro probe of mixed function oxidase activity [proceeding]. Br J Clin Pharmacol. 9:284P.
• Brodie MJ; Boobis AR; Dollery CT; Hillyard CJ; Brown DJ; Macintyre I; Park BK. (Mar 1980). Rifampicin and vitamin D metabolism in man [proceedings]. Br J Clin Pharmacol. 9:286P-287P.
• McManus ME; Boobis AR; Pacifici GM; Frempong RY; Brodie MJ; Kahn GC; Whyte C; Davies DS. (11 Feb 1980). Xenobiotic metabolism in the human lung. Life Sci. 26:481-487.
• Reid JL; Jones DH; Fitzgerald G; Davies D; Boobis A. (1980). Catecholamine turnover in essential hypertension. Clin Exp Hypertens. 2:395-408.
• BOOBIS AR; DAVIES DS; PACIFICI GM. (1 Jan 1980). DEVELOPMENTAL-CHANGES IN THE INDUCIBILITY OF DRUG-METABOLIZING-ENZYMES BY 3-METHYLCHOLANTHRENE IN HEPATIC AND EXTRA-HEPATIC TISSUES OF THE RABBIT. BRITISH JOURNAL OF PHARMACOLOGY. 69:P321-P322. Author weblink.
• Legraverend C; Nebert DW; Boobis AR; Pelkonen O. (1980). DNA binding of benzo[a]pyrene metabolites. Effects of substrate and microsomal protein concentration in vitro, dietary contaminants, and tissue differences. Pharmacology. 20:137-148.
• Mucklow JC; Rawlins MD; Brodie MJ; Boobis AR; Dollery CT. (19 Jul 1980). Drug oxidation in Asian vegetarians. Lancet. 2:151.
• Boobis AR; Brodie MJ; Kahn GC; Fletcher DR; Saunders JH; Davies DS. (Jan 1980). Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol. 9:11-19.
• BLAIR IA; BOOBIS AR; DAVIES DS; CRESP TM. (1 Jan 1980). PARACETAMOL OXIDATION - SYNTHESIS AND REACTIVITY OF N-ACETYL-P-BENZOQUINONEIMINE. TETRAHEDRON LETTERS. 21:4947-4950. Author weblink DOI.
• BRODIE MJ; BOOBIS AR; DOLLERY CT; HILLYARD CJ; BROWN DJ; MACINTYRE I; PARK BK. (1 Jan 1980). RIFAMPICIN AND VITAMIN-D METABOLISM IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 9:P286-P287. Author weblink.
• BAILLIE TA; BOOBIS AR; DAVIES DS; FRANK H; MURRAY S. (1 Jan 1980). STEREOSELECTIVE EXCRETION OF 3-METHOXY-4-HYDROXYPHENYLETHYLENE GLYCOL SULFATE IN THE DOG. BRITISH JOURNAL OF PHARMACOLOGY. 69:P320-P321. Author weblink.
• Boobis AR; Murray S; Jones DH; Reid JL; Davies DS. (Apr 1980). Urinary conjugates of 4-hydroxy-3-methoxyphenylethylene glycol do not provide an index of brain amine turnover in man. Clin Sci (Lond). 58:311-316.
• Pacifici GM; Boobis AR; Brodie MJ; Davies DS. (Oct 1979). A rapid sensitive assay for glutathione S-epoxidetransferase activity: species differences in the activity of the hepatic enzyme [proceedings]. Biochem Soc Trans. 7:1060-1061.
• Boobis AR; Brodie MJ; Bulpitt CJ; Davies DS. (Jul 1979). Environmental factors affecting monooxygenase activity of microsomal fractions of human liver biopsies [proceedings]. Br J Pharmacol. 66:426P-427P.
• Boobis AR; Davies DS; Lewis KM. (Jul 1979). Resolution and reconstitution of the forms of hepatic cytochrome P-450 from rabbits [proceedings]. Br J Pharmacol. 66:427P.
• Boobis AR; Brodie MJ; Davies DS; Murray S; Toverud EL. (Apr 1979). Substrate-metabolite profiles in the study of inter-individual differences in drug oxidation in man [proceedings]. Br J Clin Pharmacol. 7:415P-416P.
• BOOBIS AR; BRODIE MJ; DAVIES DS; KAHN GC; WHYTE C. (1 Jan 1979). BIPHASIC MICHAELIS-MENTEN KINETICS FOR ETHOXYCOUMARIN AND PHENACETIN METABOLISM BY HUMAN AND RAT HEPATIC MONO-OXYGENASES. BRITISH JOURNAL OF PHARMACOLOGY. 66:P428-P428. Author weblink.
• Nebert DW; Shum S; Boobis AR; Atlas SA. (1979). Developmental pharmacology and the Ah locus: regulatory and temporal genes affecting teratogenesis. Acta Biol Med Ger. 38:519-529.
• BRODIE MJ; BOOBIS AR; KHAN GC; DAVIES DS; FLETCHER DR; SAUNDERS JH. (1 Jan 1979). EFFECTS OF LIVER-DISEASE AND SMOKING ON HEPATIC MONO-OXYGENASE ACTIVITY INVITRO. CLINICAL SCIENCE. 56:P27-P27. Author weblink.
• Boobis AR; Nebert DW; Pelkonen O. (1979). Effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. Biochem Pharmacol. 28:111-121.
• BOOBIS AR; BRODIE MJ; BULPITT CJ; DAVIES DS. (1 Jan 1979). ENVIRONMENTAL-FACTORS AFFECTING MONO-OXYGENASE ACTIVITY OF MICROSOMAL FRACTIONS OF HUMAN-LIVER BIOPSIES. BRITISH JOURNAL OF PHARMACOLOGY. 66:P426-P427. Author weblink.
• BOOBIS AR; KOURI RE; NEBERT DW. (1 Jan 1979). GENETIC DIFFERENCES IN THE BINDING OF BENZO[A]PYRENE METABOLITES TO DNA IN THE MOUSE. CANCER DETECTION AND PREVENTION. 2:83-111. Author weblink.
• Pelkonen O; Boobis AR; Levitt RC; Kouri RE; Nebert DW. (1979). Genetic differences in the metabolic activation of benzo[a]pyrene in mice. Attempts to correlate tumorigenesis with binding of reactive intermediates to DNA and with mutagenesis in vitro. Pharmacology. 18:281-293.
• BOOBIS AR; DAVIES DS; LEWIS KM. (1 Jan 1979). RESOLUTION AND RECONSTITUTION OF 2 FORMS OF HEPATIC CYTOCHROME-P-450 FROM RABBITS. BRITISH JOURNAL OF PHARMACOLOGY. 66:P427-P427. Author weblink.
• Thorgeirsson SS; Atlas SA; Boobis AR; Felton JS. (1979). Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals. Biochem Pharmacol. 28:217-226.
• BOOBIS AR; BRODIE MJ; DAVIES DS; MURRAY S; TOVERUD EL. (1 Jan 1979). SUBSTRATE METABOLITE PROFILES IN THE STUDY OF INTER-INDIVIDUAL DIFFERENCES IN DRUG OXIDATION IN MAN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 7:P415-P416. Author weblink.
• Boobis AR; Brodie MJ; Davies DS; Fletcher DR; Saunders JH. (Nov 1978). Mixed function oxidase activity in microsomal fractions of human liver biopsy specimens [proceedings]. Br J Clin Pharmacol. 6:449P-450P.
• Boobis AR; Atlas SA; Nebert DW. (1978). Carcinogenic benzo(a)pyrene metabolites bound to DNA: metabolic formation by human cultured lymphocytes and by human liver microsomes. Pharmacology. 17:241-248.
• BOOBIS AR; BRODIE MJ; DAVIES DS; FLETCHER DR; SAUNDERS JH. (1 Jan 1978). MIXED-FUNCTION OXIDASE ACTIVITY IN MICROSOMAL FRACTIONS OF HUMAN LIVER-BIOPSY SPECIMENS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 6:P449-P450. Author weblink.
• Pelkonen O; Boobis AR; Yagi H; Jerina DM; Nebert DW. (Mar 1978). Tentative identification of benzo[a]pyrene metabolite-nucleoside complexes produced in vitro by mouse liver microsomes. Mol Pharmacol. 14:306-322.
• Atlas SA; Boobis AR; Felton JS; Thorgeirsson SS; Nebert DW. (10 Jul 1977). Ontogenetic expression of polycyclic aromatic compound-inducible monooxygenase activities and forms of cytochrome P-450 in rabbit. Evidence for temporal control and organ specificity of two genetic regulatory systems. J Biol Chem. 252:4712-4721.
• Baillie TA; Boobis AR; Davies DS; Jones DH; Murray S; Reid JL. (Jun 1977). Studies on the metabolic fate of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) in man [proceedings]. Br J Pharmacol. 60:280P.
• Boobis AR; Nebert DW; Felton JS. (Mar 1977). Comparison of beta-naphthoflavone and 3-methylcholanthrene as inducers of hepatic cytochrome(s) P-448 and aryl hydrocarbon (benzo[a]pyrene) hydroxylase activity. Mol Pharmacol. 13:259-268.
• Boobis AR; Reinhold C; Thorgeirsson SS. (15 Aug 1977). Induction of aryl hydrocarbon (benzo[a]pyrene) hydroxylase and 2-acetylaminofluorene N-hydroxylase by polycyclic hydrocarbons in regenerating liver from inbred strains of mice. Biochem Pharmacol. 26:1501-1505.
• BOOBIS AR; NEBERT DW; ATLAS SA. (1 Jan 1976). BINDING OF BENZO[A]PYRENE METABOLITES TO DNA INVITRO CATALYZED BY HUMAN LYMPHOCYTES. CLINICAL RESEARCH. 24:A374-A374.
• BOOBIS AR; FELTON JS. (1 Jan 1976). COMPARISON OF MOUSE HEPATIC ARYL-HYDROCARBON HYDROXYLASE INDUCTION BY 3-METHYLCHOLANTHRENE AND BETA-NAPHTHOFLAVONE. FEDERATION PROCEEDINGS. 35:708-708. Author weblink.
• BOOBIS AR; NEBERT DW. (1 Jan 1976). GENETIC DIFFERENCES IN CARCINOGENIC INDEX OF BENZO[A]PYRENE INVIVO AND BINDING OF ITS METABOLITES TO DNA INVITRO. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 17:48-48. Author weblink.
• Boobis AR; Nebert DW. (1976). Genetic differences in the metabolism of carcinogens and in the binding of benzo (a) pyrene metabolites to DNA. Adv Enzyme Regul. 15:339-362.
• BOOBIS AR; NEBERT DW. (1 Jan 1976). INDUCTION AND INHIBITION OF FORMATION OF BENZO[A]PYRENE METABOLITES THAT COVALENTLY BIND TO DNA BY INBRED MICE. PHARMACOLOGIST. 18:210-210. Author weblink.
• THORGEIRSSON SS; NELSON WL; BOOBIS AR; REINHOLD CE. (1 Jan 1976). METABOLISM, MUTAGENICITY AND CARCINOGENICITY OF 2-ACETYLAMINOFLUORENE AND RELATED COMPOUNDS. HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE. 357:1059-1059. Author weblink.
• ATLAS SA; THORGEIRSSON SS; BOOBIS AR. (1 Jan 1976). ONTOGENIC EXPRESSION OF AROMATIC HYDROCARBON-INDUCIBLE MONO-OXYGENASES IN RABBIT. FEDERATION PROCEEDINGS. 35:1421-1421. Author weblink.
• Atlas AS; Thorgeirsson SS; Boobis AR; Kumaki K; Nebert DW. (15 Nov 1975). Differential induction of murine Ah locus-associated monooxygenase activities in rabbit liver and kidney. Biochem Pharmacol. 24:2111-2116.
• Powis G; Boobis AR. (1 Oct 1975). Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds. Biochem Pharmacol. 24:1771-1776.
• Boobis AR; Gibson A; Stevenson RW. (15 Feb 1975). Ethanol protection against hemicholinium toxicity in mice. Biochem Pharmacol. 24:485-488.
• BOOBIS AR; REINHOLD C; THORGEIRSSON SS. (1 Jan 1975). INDUCTION BY POLYCYCLIC-HYDROCARBONS OF ARYL-HYDROCARBON (BENZO[A]PYRENE) HYDROXYLASE IN REGENERATING LIVER OF INBRED STRAINS OF MICE. PHARMACOLOGIST. 17:249-249. Author weblink.
• Powis G; Boobis AR. (1 Feb 1975). The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. Biochem Pharmacol. 24:424-426.
• Boobis AR; Powis G. (Mar 1975). The metabolism and disposition of aniline in the isolated blood-perfused liver of the rat. Drug Metab Dispos. 3:63-68.
• THORGEIRSSON SS; ATLAS SA; BOOBIS AR; FELTON JS; NEBERT DW. (1 Jan 1975). VARYING SUBSTRATE SPECIFICITIES OF CYTOCHROME P1450 IN POLYCYCLIC HYDROCARBON-TREATED ANIMALS OF 5 SPECIES. PHARMACOLOGIST. 17:217-217. Author weblink.
• Boobis AR; Powis G. (15 Dec 1974). The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. Biochem Pharmacol. 23:3377-3384.
• Boobis A; Powis G. (Sep 1973). Proceedings: The isolated perfused rat liver in the study of the metabolism of foreign compounds. Br J Pharmacol. 49:185P-186P.
• Boobis AR; Pollock D; Gillespie JS. (Oct 1971). Influence of phenobarbitone on liver regeneration and microsomal N-demethylating activity in partially hepatectomized rats. Br J Pharmacol. 43:458P-459P.

Books

• Anadon A; Arnold D; Boisseau J; Boobis AR; Ellis R; Greenlees K; McLean JG; MacNeil J; et alRojas Martinez JL; Miterna ES; Palerm-Neta J; Soback S; Stephany RW. Evaluation of certain veterinary drug residues in food: 58th Report of the Joint FAO/WHO Expert Committee on Food. (2002).
• Boobis AR; Chen BH; Moretto A; Priestly BG; Banasiak U; Dutra Caldas E; Funk S; Hamilton DJ; et alOssendorp BC. Pesticide Residues in Food:2001: toxicological evaluations. (2002).
• Anadon A; Arnold D; Boisseau J; Boobis AR; Ellis R; Greenlees K; McLean JG; MacNeil J; et alRojas Martinez JL; Miterna ES; Palerm-Neta J; Soback S; Stephany RW. Toxicological evaluation of certain veterinary drug residues in food. (2002).
• Anadon A; Appelgren L; Arnold D; Boisseau J; Boobis AR; Kinabo LDB; McLean JG; MacNeil JD; et alMiller MA; Palermo-Neto J; Rojas Martinez JL; Soback S; Stephany RW. Evaluation of certain veterinary drug residues in food: fifty-fourth report of the Joint FAO/WHO expert Committee on Food Additives. (2001).
• Banasiak U; Boobis AR; Caldas ED; Chen B; Funk S; Hamilton DJ; Moretto A; Ossendorp BC; et alPriestly BG. Pesticide Residues in Food - 2001. (2001).
• Banasiak U; Boobis AR; Borzelleca JF; Caldas ED; Calumpang SMF; Fenner-Crisp P; Funk S; Hakansson H; et alHajslova J; Hamilton DJ; Moretto A; Ogura A; Ossendorp BC; Priestly BG; Soliman SA. Pesticides Residues in Food - 2000. (2001).
• Banasiak U; Calumpang SMF; Boobis AR; Borzelleca JF; Caldas ED; Fenner-Crisp P; Funk S; Hajslova J; et alHakansson H; Hamilton DJ; Moretto A; Ogura A; Ossendorp BC; Priestly BG; Soliman SA. Pesticides Residues in Food - 2000: toxicological evaluations. (2001).

Chapters in books

• Pelkonen O; Boobis AR; Kremers P. Interindividual variation of P450 enzymes in vitro and its causes. 10:269-332. (2001).

Conferences

• Flari V; Gosling JP; Hart A; Boobis A; Idahosa-Taylor E; Rushton L. Eliciting expert knowledge about the form of the dose-response curve for genotoxic carcinogens at low exposures and the implications for a level of concern. 47th Congress of the European-Societies-of-Toxicology, 28 Aug 2011 - 31 Aug 2011. 205:S260-S260. ELSEVIER IRELAND LTD (28 Aug 2011). Author weblink DOI.
• Boobis A. Integrating miRNAs within current safety assessment: Future perspectives. 47th Congress of the European-Societies-of-Toxicology, 28 Aug 2011 - 31 Aug 2011. 205:S31-S32. ELSEVIER IRELAND LTD (28 Aug 2011). Author weblink DOI.
• Dorne JL; Doerge D; Boobis A. Mechanistic basis for the harmonisation of ecological and human risk assessment. 47th Congress of the European-Societies-of-Toxicology, 28 Aug 2011 - 31 Aug 2011. 205:S9-S9. ELSEVIER IRELAND LTD (28 Aug 2011). Author weblink DOI.
• Boobis A. Risk assessment needs 21st century rationality as well as 21st century science. 47th Congress of the European-Societies-of-Toxicology, 28 Aug 2011 - 31 Aug 2011. 205:S1-S1. ELSEVIER IRELAND LTD (28 Aug 2011). Author weblink DOI.
• Koster S; Boobis A; Carlander D; Cubberley R; Hollnagel H; Richling E; Wurtzen G; Galli CL. The application of the TTC concept to unknown substances found in the analysis of foods. 47th Congress of the European-Societies-of-Toxicology, 28 Aug 2011 - 31 Aug 2011. 205:S28-S28. ELSEVIER IRELAND LTD (28 Aug 2011). Author weblink DOI.
• Boobis A. Critical analysis of literature on low dose synergy for use of TTC in screening chemical mixtures for risk assessment. 46th Congress of the European-Societies-of-Toxicology, 13 Sep 2009 - 16 Sep 2009. 189:S51-S51. ELSEVIER IRELAND LTD (13 Sep 2009). Author weblink DOI.
• Burnett K; Boobis A; Pollitt F; Battershill J. Risk assessment of mixtures of mutagenic and carcinogenic chemicals: A regulatory perspective from the UK. 46th Congress of the European-Societies-of-Toxicology, 13 Sep 2009 - 16 Sep 2009. 189:S271-S271. ELSEVIER IRELAND LTD (13 Sep 2009). Author weblink DOI.
• Idahosa E; Rushton L; Boobis AR. Systematic review of epidemiological evidence for use in the framework approach for analysing the human relevance of an animal mode of action. Annual Congress of the British-Toxicological-Society, 6 Apr 2008 - 9 Apr 2008. 253:15-15. ELSEVIER IRELAND LTD (20 Nov 2008). Author weblink DOI.
• Zhu Z; Boobis AR; Edwards RJ. Proteomic analysis of the differential effects of estrogens on human breast cancer cells. Annual Congress of the British-Toxicological-Society, 15 Apr 2007 - 18 Apr 2007. 240:167-168. ELSEVIER IRELAND LTD (6 Nov 2007). Author weblink DOI.
• Boobis AR. Prediction of drug metabolism on the basis of in vitro approaches. 8th European Congress of Pharmaceutical Sciences, 17 Oct 2004 - 20 Oct 2004. 23:S8-S9. ELSEVIER SCIENCE BV (1 Oct 2004). Author weblink.
• O'Leary KA; Edwards RJ; Town M; Boobis AR. Polymorphic variation in PON1 affects the detoxitication of diazoxon in serum. BTS 2004 Annual Congress. 202:89-90. (30 Sep 2004).
• Coban T; Kapucuoglu N; Raunio H; Pelkonen O; Edwards RJ; Boobis AR; Iscan M. Expression of CYP3A4 in human breast tumors. 7th European ISSX Meeting. 36:92-92. (Aug 2004).
• Jones HA; Boobis AR. Cellular and biochemical responses to intrapulmonary particulates. 10th International Congress of Toxicology, 11 Jul 2004 - 15 Jul 2004. 197:150-151. ACADEMIC PRESS INC ELSEVIER SCIENCE (15 Jun 2004). Author weblink.
• Fang M; Boobis AR; Edwards RJ. The search for novel protein biomarkers of neurotoxicity using SELDI-TOF mass spectrometry. 10th International Congress of Toxicology, 11 Jul 2004 - 15 Jul 2004. 197:318-318. ACADEMIC PRESS INC ELSEVIER SCIENCE (15 Jun 2004). Author weblink.
• Boobis AR. Chronic health effects from pesticide exposure. 5th Congress of Toxicology in Developing Countries. 191:6-6. (15 Sep 2003).
• Anadon A; Arnold D; Boisseau J; Boobis AR; Ellis R; Greenlees K; McLean JG; MacNeil J; et alMartinez JLR; Mitema ES; Palermo-Neto J; Soback S; Stephany RW; Cerniglia CE; Chamberlain P; Suarez AF; Frielander LG; Herrman JL; Leutzow M; Mitsumori K; Page SW; Pronk MEJ; Reeves PT; Renshaw D; Roberts G; AliAbadi FS; Sundlof S; Swan GE. Evaluation of certain veterinary drug residues in food. 58th Joint FAO/WHO Expert Committee Meeting on Food Additives, 21 Feb 2002 - 27 Feb 2002. 911:1-66. WORLD HEALTH ORGANIZATION (1 Jan 2002). Author weblink.
• Anadon A; Appelgren LE; Arnold D; Boisseau J; Boobis AR; Kinabo LDB; McLean JG; MacNeil JD; et alMiller MA; Palermo-Neto J; Martinez JLR; Soback SS; Stephany RW. A meeting of the Joint FAO/WHO Expert Committee on Food Additives was held at WHO Headquarters, Geneva, from 15 to 24 February 2000. Meeting of the Joint FAO/WHO Expert Committee on Food Additives. 900:1-96. (2001).
• Gooderham NJ; Lynch AM; Yadollahi-Farsani M; Murray S; Boobis AR; Davies DS. Metabolism and genotoxicity of food-derived heterocyclic amines. Symposium on Drug Metabolism - Towards the Next Millennium. 25:127-136. (1998).
• Boobis AR. Mammalian in vitro systems: predictive value in drug metabolism. 2nd World Congress on Alternatives and Animal Use in the Life Sciences, 20 Oct 1996 - 24 Oct 1996. 27:825-833. ELSEVIER SCIENCE PUBL B V (1 Jan 1997). Author weblink.
• Clifford CP; Adams DA; Murray S; Taylor GW; Wilkins MR; Boobis AR; Davies DS. Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Clinical Pharmacology Section of the Joint Meeting with the Pharmacological-Society-of-Canada / Canadian-Society-for-Clinical-Pharmacology, 10 Jul 1996 - 12 Jul 1996. 42:P662-P662. BLACKWELL SCIENCE LTD (1 Nov 1996). Author weblink.
• Boobis AR. Interindividual variability in metabolic activation in humans in vivo. IPCS/UK DOH Workshop on Variability in Toxic Response - Human and Environmental, 8 Mar 1995 - 10 Aug 1995. 2:161-163. ELSEVIER SCIENCE BV (15 Oct 1996). Author weblink DOI.
• Riedl AG; Watts PM; Edwards RJ; Boobis AR; Jenner P. Brain cytochrome P450 in the rat. 656th Meeting of the Biochemical-Society. 24:S52-S52. (Feb 1996).
• BOOBIS AR. MOLECULAR-BASIS FOR DIFFERENCES IN SUSCEPTIBILITY TO TOXICANTS - INTRODUCTION. 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY : TOXICOLOGY FROM DISCOVERY AND EXPERIMENTATION TO THE HUMAN PERSPECTIVE. 64-5:109-113. (Dec 1992).
• DAVIES DS; FAWTHROP DJ; NASSERISINA P; WILSON JW; HARDWICK SJ; BOOBIS AR. PARACETAMOL TOXICITY AND ITS PREVENTION BY CYTOPROTECTION WITH ILOPROST. 6TH INTERNATIONAL CONGRESS OF TOXICOLOGY : TOXICOLOGY FROM DISCOVERY AND EXPERIMENTATION TO THE HUMAN PERSPECTIVE, 28 Jun 1992 - 3 Jul 1992. 64-5:575-580. ELSEVIER SCI IRELAND LTD (1 Dec 1992). Author weblink DOI.
• BOOBIS AR; GOODERHAM NJ; MURRAY BP; MURRAY S; LYNCH A; SESARDIC D; DAVIES DS. ABSORPTION AND DISPOSITION OF MEIQX IN MAN - LESSONS FOR HUMAN DOSIMETRY. INTERNATIONAL SYMP ON TRENDS IN BIOLOGICAL DOSIMETRY, 23 Oct 1990 - 27 Oct 1990. 372:89-98. WILEY-LISS, INC (1 Jan 1991). Author weblink.
• GOODERHAM NJ; MURRAY BP; MURRAY S; BOOBIS AR; DAVIES DS. EXPOSURE TO, AND ACTIVATION OF, THE FOOD DERIVED MUTAGENIC HETEROCYCLIC AMINE MEIQX. 5TH INTERNATIONAL CONF ON ENVIRONMENTAL MUTAGENS. 340:67-76. (1990).
• SESARDIC D; EDWARDS RJ; DAVIES DS; BOOBIS AR. HEPATIC SUPPRESSION OF CYTOCHROME-P450C CATALYZED O-DEETHYLATION OF PHENACETIN. 6TH INTERNATIONAL CONF ON BIOCHEMISTRY AND BIOPHYSICS OF CYTOCHROME P-450. 870-873. (1989).